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Objective: We intend to investigate the ability of H-FABP levels to identify 
significant coronary artery disease in low- to intermediate-risk patients with 
suspected acute coronary syndrome (ACS). 
Background: H-FABP is a small intracellular protein involved in the 
transport and buffering of fatty acids in cardiac myocytes. There is an 
increasing evidence base for the utility of H-FABP as a cardiac biomarker for 
the early diagnosis of ACS. Levels have been shown to provide incremental 
prognostic information about future risk of myocardial infraction (MI) and 
death, independent of traditional risk factors and troponin levels. 
Methods: 238 patients presenting with possible ACS were recruited as they 
attended the Emergency Department (ED) of a major UK teaching hospital. 
Venous blood samples were drawn at presentation, 90 minutes later, and 
after 12 hours from index symptoms. H-FABP was measured using the 
RANDOX Immunoturbidometric Immunoassay. Computerised axial 
tomography coronary artery calcium scoring (CTCS) was used as a marker 
of coronary atheroma burden, combined with clinical assessment for the 
detection of obstructive coronary artery disease (CAD). 
Results: There was a statistically significant positive correlation between H-
FABP and CTCS, independent of age and renal function. 
Used on its own as a continuous variable, H-FABP was poor at predicting 
Agatston CTCS >10, and the clinical demonstration of obstructive coronary 
disease (areas under the ROC curve 0.6-0.7). When used as part of a 
multifactorial model to predict these endpoints H-FABP was, however, a 
more powerful predictor than some traditional risk factors such as smoking 
status, diabetes, hypertension, as well as renal function. 
H-FABP showed the greatest promise when used as a dichotomous variable 
within what we termed a ‘triple rule-out’ strategy. Here, H-FABP was used 
alongside the ECG and troponin to help identify patients at low risk of 
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obstructive coronary artery disease, and tertiary events within a median 
follow-up period of 406 days (death from a cardiovascular cause, myocardial 
infarction, coronary revascularisation). Using a H-FABP cut-off at the 50th 
centile (3.16 μg/l), the triple rule-out strategy had a 96.4% negative 
predictive value (95% CI 86.6%-99.3%), and sensitivity of 83.3% (95% CI 
50.8%-97.1%). 31% of the recruited population fell into the rule-out group. 
The triple rule-out strategy was validated for mortality on a cohort of 483 
patients from the FAB2 study (Viswanathan et al., 2010). 19% of patients 
met rule-out criteria, with a 2.2% all-cause six year mortality, as compared to 
a 20.6% all-cause six year mortality for patients that did not. In the rule-out 
group no deaths were seen within the first 18 months. This equates to an all-
cause six year mortality sensitivity of 97.5% (95% CI 90.5%-99.6%) and 
negative predictive value of 97.8% (95% CI 91.4%-99.6%). 
Conclusion: The analyses demonstrate the potential for H-FABP to be used 
as part of a triple rule-out strategy, guided by clinical assessment, alongside 
the ECG and troponin to identify low risk patients as they present to the ED. 
The strategy would benefit from external validation. 
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Chest pain presentations represent a significant healthcare burden, locally 
accounting for 6% of emergency department attendances, and 27% of acute 
medical hospital admissions (Goodacre et al., 2005). When a cardiac cause 
is felt possible, current UK practice is to measure troponin, an ‘intermediate / 
late’ cardiac biomarker. If early samples are normal, patients are kept in 
hospital and troponin levels are re-assessed at least 10-12 hours after the 
onset of pain (NICE CG95). There is a growing interest in ‘early’ cardiac 
biomarkers that could allow the risk stratification of these patients at a much 
earlier stage, facilitating discharge from hospital sooner if negative, and 
potentially allowing earlier treatment when positive. 
Heart-type fatty acid binding protein (H-FABP) is a cytoplasmic protein found 
abundantly within cardiac myocytes (Glatz et al., 1997). Its small size (15 
Kd) allows it to be readily released into the circulation after both myocardial 
ischaemia and infarction. Following myocardial infarction serum levels peak 
after around 6-8 hours, and return to normal within about 24 hours (Glatz et 
al., 2002; Glatz et al., 1994). Although highly cardiac-specific, small 
concentrations are found in tissues outside the heart. Other limitations 
include its renal excretion (like troponin) potentially making it less useful in 
patients with renal impairment, and the relatively narrow diagnostic time 
window. Elevated H-FABP levels are reported in patients with atrial 
fibrillation, atrial flutter, and after electrical cardioversion. This will need to be 
taken into consideration if being used as a biomarker in these patient groups 
(Mazovets et al., 2006).  
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Figure 1.1 Three-dimentional structure of human H-FABP. 
Biochemical Journal (2001) 354, 259-266. 
 
There is a growing evidence base supporting the high potential of H-FABP 
levels in the early diagnosis of ACS, the risk assessment of patients 
presenting with chest pain, and emerging evidence suggesting that H-FABP 
levels are closely related to angiographic findings in patients presenting with 
ACS. 
A Medline search was conducted for full reports of original research between 
January 2000 and January 2014 using the search terms “heart-type fatty 
acid-binding protein”, “fatty acid-binding protein”, “H-FABP”, “FABP”. The 
references of papers identified were explored to identify research not 
identified in the original search. Studies including less than 100 patients 
were excluded, as were studies solely using point-of-care methods. 
1.1 H-FABP as a Diagnostic Marker 
There are now a number of studies published in this area, although many 
include fewer than 100 patients, and used different H-FABP assays. The 
conclusions of meta analyses are mixed. The systematic review and critical 
appraisal by Dekker et al published in 2010 concluded that H-FABP seemed 
to be a promising biomarker in the early assessment of ACS (Dekker et al., 
2010). Slot et al examined 16 studies (3709 patients, prevalence of MI 13–
74%, male gender 49–84%, median age 64–76 years). For the diagnosis of 
MI the summary estimate was a sensitivity of 84% (95% CI 76% to 90%) and 
specificity of 84% (95% CI 76% to 89%). They conclude that H-FABP does 
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not fulfil the requirements needed for a safe and early diagnosis of AMI 
when used as a stand-alone test (Slot et al., 2010).  
The met-analysis by Carroll et al included eight studies of quantitative H-
FABP and nine studies of qualitative H-FABP. The summary estimates of 
sensitivity and specificity were 81% (95% CI 50% to 95%) and 80% (26% to 
98%) respectively for the quantitative assays and 68% (11% to 97%) and 
92% (20% to 100%) respectively for the qualitative assays. Four studies 
reported the sensitivity of troponin combined with H-FABP at presentation in 
which the combination was considered positive if either test was positive. 
The addition of H-FABP to troponin increased sensitivity from 42–75% to 
76–97% but decreased specificity from 94–100% to 65–93%. They conclude 
that H-FABP may have a role alongside troponin in improving early 
sensitivity but comparison with high sensitivity troponin assays is required 
(Carroll et al., 2012). 
In a study of 705 patients presenting with suspected cardiac chest pain, in 
blood drawn at the time of presentation (median of 3.5 hours after symptom 
onset), H-FABP was demonstrated to be superior to CKMB, myoglobin and 
troponin for the detection of MI (area under ROC curve (AUC) 0.86 (95% CI 
0.82-0.90)) (Body et al., 2011b). Although in this study no single biomarker 
could enable clinically acceptable exclusion of MI on its own, the 
combination of troponin I and H-FABP was found to be the optimal 
combination. Similarly, in 485 patients Gururajan et al demonstrated H-
FABP, measured 3-6 hours after the onset of pain, to be a good 
discriminator between patients with ACS as compared with those felt to have 
non-cardiac symptoms and normal controls (AUC 0.97, 95% CI 0.95-0.98) 
(Gururajan et al., 2010). 
Collinson et al randomised 850 low-risk patients presenting with chest pain 
to either diagnostic assessment by a cardiac panel measured by point-of-
care testing or to diagnosis when biomarker measurement was based on 
central laboratory testing. Patients with ECG changes of myocardial 
infarction or high-risk ACS were excluded. Blood was drawn on admission 
and 90 minutes from admissions for point-of-care measurement of TnI, 
CKMB, and myoglobin. Samples were drawn at the same time for central 
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laboratory analysis of TnI, TnT, H-FABP, and copeptin. The authors 
conclude that the measurement of Tn was the single best test, but admission 
measurement alone did not achieve adequate diagnostic efficiency for rule-
out. Diagnostic sensitivity was improved by measurement of H-FABP in 
addition to Tn (Collinson et al., 2014). 
The absolute reported sensitivity and specificity of H-FABP for the early 
diagnosis of ACS varies in the literature. This may reflect the different 
assays used, diverse characteristics of the recruited populations, combined 
with variations in the way ACS is categorised and the time blood samples 
were drawn. As an example, in the study by Charpentier et al using samples 
from 677 patients with suspected ACS on admission to the ED, H-FABP was 
predictive of the diagnosis of ACS with an OR of 4.65 (95% CI 2.39-9.04), 
specificity of 96.8% (95% CI 95.4%-98.1%), but low sensitivity of 13.5% 
(95% CI 10.9%-16.1%) (Charpentier et al., 2010). In this study H-FABP, 
measured using an immunodetection with CardioDetect assay, was not felt 
to add significantly to standard diagnostic tools. Figiel et al demonstrated a 
similar specificity for diagnosing non-ST segment elevation MI in 100 
patients, using blood drawn at presentation, although sensitivity in this study 
was found to be much higher at 94.7% (CI not available) (Figiel et al., 2008). 
This study also used the CardioDetect assay, although the recruited 
population was quite different: in this study all patients had a confirmed 
rather than suspected diagnosis of ACS. Cavus et al reported a sensitivity of 
97.6% on samples taken during the first hour from presentation (CI not 
available) (Cavus et al., 2006).  
In the study by McMahon et al H-FABP was found to have a high negative 
predictive value (NPV) for MI, 93% at 0 to 3 hours from pain onset, 
increasing to 97% at 3 to 6 hours (CI not available for this study). Combining 
H-FABP with troponin increases this to 94 and 98% respectively. In this 
study, which also assessed CKMB, myoglobin, and TnI, H-FABP had the 
greatest sensitivity at 0 to 3 hours (64.3%), 3 to 6 hours (85.3%), and 6 to 12 
hours (89.9%) after chest pain onset (an average superiority of 13.6% over 
Tn). The combination of TnI measurement with H-FABP increased this 
sensitivity to 71.4% at 0 to 3 hours, 88.2% at 3 to 6 hours, and 92.4% at 6 to 
12 hours demonstrating an increase in sensitivity of 20.6% for the 
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combination marker approach at 3 to 6 hours. Troponin, on the other hand, 
demonstrated a higher specificity than H-FABP at 0 to 3 hours (93.3% 
compared with 84.2%) and at 3 to 6 hours (94.3% compared with 88.7% for 
H-FABP). At 6 to 12 hours, the specificity of H-FABP was comparable with 
that of TnI (93.5% for H-FABP compared with 94.2% for TnI) (McMahon et 
al., 2012).  
Numerous other studies support the use of H-FABP for the early diagnosis 
of MI (Nakata et al., 2003; Okamoto et al., 2000; Orak et al., 2010; Ruzgar et 
al., 2006; Valle et al., 2008; Kim et al., 2011; Kim et al., 2010). 
1.2 H-FABP as a Prognostic Marker 
One of the largest published studies on H-FABP, conducted by our 
department, examined the ability of H-FABP levels to predict long term 
mortality in patients with confirmed ACS. This used samples taken at 12-24 
hours after chest pain from 1448 consecutive consenting patients with a 
confirmed diagnosis of ACS. Specifically patients were included in the study 
if they fulfilled the revised European Society of Cardiology / American 
College of Cardiology definition of MI: raised troponin value taken 12-24 
hours after the onset of symptoms accompanied by at least one of the 
following: 1) ischaemic symptoms; 2) development of pathological Q waves 
on the ECG; 3) ECG changes indicative of ischaemia; 4) delivery of primary 
coronary angioplasty and 5) compatible post-mortem findings. Some 
unstable angina patients were also included on the basis of clinical and ECG 
diagnosis. H-FABP was strongly predictive of all-cause mortality at one year 
after index hospital admission, independent of traditional clinical risk factors, 
and across the whole spectrum of ACS (unstable angina, NSTEMI and 
STEMI presentations). Of great interest, was the ability of H-FABP levels to 
separate troponin negative patients into a low and high risk group. Unstable 
angina patients with a low H-FABP level (<5.8 µg/l) had a 1-year all-cause 
mortality of 2.1%, whereas patients with levels above this cut off had a 
mortality of 22.9%. The occurrence of a negative test for both H-FABP and 
troponin was associated with zero mortality prior to six months (Kilcullen et 
al., 2007).  
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Figure 1.2 All-cause mortality by troponin and H-FABP clinical cut-offs.  
Note the ability of H-FABP levels to separate patients with negative 
troponin into low and high risk groups. TnI = troponin I, - = below 
clinical cut-off, + = above clinical cut-off. JACC (2007) 50, 2061-7. 
 
A follow-on study further examined the role of H-FABP in the low to medium 
risk population by using 1080 consecutive presenting patient with suspected 
rather than confirmed ACS (Viswanathan et al., 2010). All individuals aged 
18 years or above with chest pain of possible or definite cardiac aetiology 
were deemed eligible for recruitment, irrespective of ECG changes. 79% of 
these patients had negative troponin results ≥ 12 hours from pain. The risk 
of death or MI increased with increasing H-FABP levels, confirming the 
ability of H-FABP to predict events independent of other clinical risk factors, 
including troponin (Advia TnI-Ultra assay). The findings from these two 
studies are in keeping with those reported by O’Donoghue et al using 
samples taken form patients recruited into the OPUS-TIMI 16 trial 
(O'Donoghue et al., 2006). 
Garcia-Valdecasas et al demonstrated that H-FABP, measured within the 
first 3-6 hours after the onset of chest pain, was not only more sensitive than 
TnI in the early diagnosis of MI, but was an independent predictor of events 
within a 6-month follow-up (Garcia-Valdecasas et al., 2011). Similarly, the 
study by Inoue et al utilising blood drawn at presentation from 432 patients, 
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concluded that H-FABP offered similar diagnostic performance to hsTnT for 
the rule-out of ACS (Inoue et al., 2011). 
Numerous other studies confirm the prognostic potential of H-FABP (Suzuki 
et al., 2005; Erlikh et al., 2005). 
1.3 Relating raised H-FABP to Stenotic Atherosclerosis 
My literature search revealed only one study examining the correlation 
between H-FABP levels and coronary artery stenosis. In a study of 93 
patients with ACS presenting within two hours of onset of chest pain, H-
FABP was measured at 2, 4, and 6 hours from symptom onset. All patients 
underwent coronary angiography. Peak H-FABP levels were seen at 4 
hours. Measured at 2 hours, the sensitivity of H-FABP for at least 50% 
stenosis was 70%, rising to 85% at four hours for ≥50% stenosis, and 88% 
at four hours for ≥70% stenosis. The sensitivity and positive predictive value 
for revascularisation was 89 and 80% respectively at four hours (Kalay et al., 
2010). There are no published studies examining the correlation between H-
FABP and total atherosclerosis burden (i.e. a non-obstructive and 
obstructive coronary artery disease end-point). 
1.4 Rationale for Avenue of Original Research Chosen 
The majority of patients presenting to the ED with chest pain have not had a 
MI and are troponin negative (Goodacre et al., 2005). Within this large group 
most patients have relatively little short- to medium-term event risk, yet there 
are a small number of patients with a very high relative risk approaching 
27% at one year (Viswanathan et al., 2010; Kilcullen et al., 2007). I believe 
that one of the primary potential uses of H-FABP is to differentiate between 
these two groups, perhaps facilitating discharge from hospital sooner if 
negative, and detecting high risk patients in need of further assessment. 
Research undertaken in our department has already demonstrated the 
powerful potential of H-FABP as an independent prognostic marker in 
patients presenting with chest pain. Despite the high potential of H-FABP as 
a cardiac biomarker, it is yet to be used on any significant scale in the UK. A 
study exploring a potential link between H-FABP’s prognostic ability 
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and coronary artery disease would substantially strengthen the case 
for the use of H-FABP measurement in clinical practice. 
The FAB3-CT study was designed to examine the relationship between H-
FABP levels and coronary artery disease in low-moderate risk patients 
presenting to the ED with suspected cardiac chest pain. All patients 
underwent a combination of clinical assessment and investigation as 
appropriate under the supervision of a Consultant Cardiologist to exclude 
obstructive coronary artery disease. In addition, CT Coronary Calcium 
Scoring was used to look for non-obstructive coronary atheroma.  
1.5 CT Coronary Calcium Scoring as a Marker of Coronary 
Atheroma Burden 
Figure 1.3 CT scan showing coronary artery calcification. 
Left main stem, left anterior descending and circumflex artery 
calcification (arrow). 
 
Many coronary events occur in the territory of coronary arteries that 
demonstrate only mild-moderate, rather than high grade stenosis (Schroeder 
and Falk, 1995). It is not surprising therefore that coronary plaque burden 
strongly relates to the risk of coronary events (Schmermund et al., 2003). 
Atherosclerosis is the only disease process associated with calcification 
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within the coronary arteries (Figure 1.3). The extent of calcification 
demonstrated by CT is therefore reflective of the overall atherosclerotic 
plaque burden (Rumberger, 2003), and large studies including more than 
25,000 patients have demonstrated the ability of CT calcium scoring to 
provide incremental and independent predictive value over traditional risk 
factors (Budoff et al., 2007). It must be remembered, however, that although 
the risk of stenotic lesions is higher with increasing calcium scores, there is 
not a one-to-one correlation. A zero calcium score is associated with a less 
than 5% probability of obstructive coronary disease, and a good prognosis 
(event rate less than 0.2% per year), but does not exclude coronary stenosis 
(Haberl et al., 2001). 
1.6 Accelerated Discharge Protocols for Patients with Chest 
Pain 
Chest pain is the second most common presenting complaint amongst 
adults attending the ED. The risk-adjusted mortality for patients with acute 
myocardial infarction (AMI) that are not hospitalised is 1.9, and for unstable 
angina 1.7 (Pope et al., 2000). As a consequence, formal diagnostic testing 
is undertaken on even very low risk patients, with the potential for false 
positive tests and unwarranted treatment, investigations and cost. 
The yield of routine provocative cardiac testing has been evaluated in a 
study involving 4181 patients. These patients attended the ED with signs or 
symptoms of possible ACS, but were not found to have resting ECG 
ischaemia or positive biomarkers. They were evaluated with either exercise 
stress testing or myocardial perfusion imaging. A subset with positive 
provocative tests underwent invasive angiography. The therapeutic yield 
was low at 0.7%, suggesting that this may not be the best approach. 
Most currently used discharge protocols rely on the results of a troponin 
measurement taken 12 hours from the index episode of chest pain. 
Accelerated Discharge Protocols (ADPs) rely on ECG findings, clinical risk 
characteristics, and cardiac biomarkers, or a combination of these, to allow 
the identification of low risk patients at an earlier stage. These patients may 
be considered suitable for early discharge from hospital, occasionally with 
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further investigations planned on an outpatient basis. The introduction of 
chest pain pathways has been shown to reduce hospital length of stay, while 
improving patient satisfaction (Siebens et al., 2010). 
It is worth bearing in mind that there is no universally accepted definition of a 
low-risk patient for ACS. The safety of an ADP relates to the number of 
missed events within the early discharge group. As previously mentioned, 
the risk-adjusted mortality for patients with AMI that are not hospitalised is 
1.9, and for unstable angina 1.7 (Pope et al., 2000). Although debate exists 
as to the acceptable level of discharge risk, this is likely to be 1-2% 
(threshold for death, AMI, revascularisation). Kline et al described a test 
threshold representing a pre-test probability of <2% for ACS: the point at 
which the risks of a false positive test outweigh the risks of untreated 
disease (Kline et al., 2005). 
In this section, I explore the current evidence base regarding ADPs. A 
Medline search was conducted for full reports of original research between 
January 2000 and January 2014 using the search terms “accelerated”, 
“chest pain”, “discharge protocol”, “diagnostic protocol”, “rule” and “critical 
pathway”. Accepting that some papers may not be indexed under terms 
related to an ‘ADP’, the references of papers identified were explored to 
identify research not identified in the original search. The studies are 
explored individually, then summarised in Table 1.1. 
ASPECT Study (Than et al., 2011) 
This was an observational multi-centre study prospectively validating the 
safety of a predefined 2-hour accelerated diagnostic protocol. Patients were 
defined as ADP negative (low risk) if the following criteria were met: TIMI 
score 0 (Thrombolysis in Myocardial Infarction), ECG showing no ischaemia, 
combined with a satisfactory point-of-care (POC) multi biomarker panel 
(MMP) performed at 0 and 2 hours (troponin I, CKMB and myoglobin). The 
primary endpoint was major adverse cardiac events (MACE) within 30 days 
after initial presentation, defined as death (not clearly non-cardiac), acute 
myocardial infarction, cardiac arrest, emergency revascularisation, 
cardiogenic shock, ventricular arrhythmia and high-degree atrioventricular 
block needing intervention. Of the 3582 patients recruited 9.8% were 
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classified as ADP low risk (352 patients). Within this group the MACE rate 
was 0.9% (3 patients). The sensitivity for 30-day MACE was 99.3% and 
specificity 11%. Cardiac troponin as a sole biomarker was sufficient alone to 
produce a sensitivity of 98.6%, although this was not an a-priori hypothesis. 
Although the ADP was able to identify low-risk patients for discharge, no 
long-term outcome data is given, and the investigators do not make 
suggestions about what to do with the patients post-discharge. 
A sub-study including 1000 of the ASPECT patients recruited in New 
Zealand, examined the impact of altering the original ADP, using point-of-
care troponin I only, high sensitivity troponin T only, including patients with a 
TIMI risk score of 0 and 1, or a combination of these strategies. The primary 
endpoint was defined as AMI and ACS (i.e. unstable angina) within 30 days, 
including prevalent events (i.e. events being the cause for the patient’s initial 
presentation). Unstable angina was defined as ischaemic symptoms with 
objective evidence of ischaemia on ECG, stress testing, or the finding of 
significant coronary artery disease. Of the 1000 patients, the diagnosis of 
ACS was made in 343 patients (34.3%), 235 with NSTEMI, and 108 with 
unstable angina. The use of early biomarker (POC-MMP, POC TnI, hsTnT) 
and ECG results alone missed many patients with ACS (sensitivity 71.5-
87.6%). Incorporating a TIMI score with any of the biomarker strategies 
improved sensitivity. The 0- to 2-hour ECG/point-of-care multi-marker panel 
(POC-MMP)/TIMI score 0 (the original ASPECT ADP) was more sensitive 
than the ECG/POC-MMP/TIMI 0-1, with a sensitivity of 99.2% for the 
diagnosis of ACS, as compared to 97%. 12.3% of patients fell into the very 
low risk ASPECT ADP category. ECG/TIMI 0/POC-TnI and ECG/TIMI 
0/hsTnT had similar sensitivities to the ASPECT ADP, but identified more 
patients as low risk (15.3 vs. 12.3%). 
ADAPT Study (Than et al., 2012) 
Another study, also by Than et al examined an ADP using serial troponin as 
the only biomarker. This ADP also included a TIMI score and ECG, 
combined with 0- and 2-hour laboratory troponin I. Most participants were 
also part of the ASPECT study. MACE data was collected at 30 days, 45 
days, and after one year. Patients were defined as ADP negative if their TIMI 
score was 0, no ischaemic ECG changes were present, and central 
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laboratory troponin I was below the institutional cut off at 0 and 2 hours. 
MACE was defined as death (not clearly non-cardiac), cardiac arrest, 
emergency revascularisation, cardiogenic shock, ventricular arrhythmia or 
high-degree atrioventricular block needing intervention, and acute 
myocardial infarction. 
Of the 1975 consenting patients, 302 patients (15.3%) had a MACE within 
30 days. 20% of patients were classified as low risk by the ADP. Only 1 
patient classified as low risk had a MACE within 30 days, giving the ADP a 
sensitivity of 99.7% (95% CI 98.1%-99.9%). By including TIMI 1 patients in 
the ADP, the proportion of patients classified as low risk increased to 38.4%, 
at the expense of a reduction in MACE sensitivity to 97%.  
This was an observational study. The majority of ADP negative patients did 
in fact go on to have further investigation within 30 days (81.1% had a stress 
test). Therapeutic and procedural interventions occurred in 18.3% and 2.0% 
of ADP negative patients, respectively. This indicates that although the ADP 
could be used to discharge some patients earlier, they would still need to 
complete outpatient investigation and review. Indeed the high level of 
interventions may have secured a better outcome for the ADP. The low 
specificity (23.5%) highlights the potential of this ADP as a rule-out rather 
than a rule-in tool. 45 day and one-year MACE event rates were not given in 
this paper. 
ADAPT (sub-group) / APACE 
Cullen et al (Cullen et al., 2013), using two patient cohorts for validation 
purposes, tested the performance of this ADP using high sensitivity troponin. 
For the first cohort (1635 patients), the sensitivity, specificity and negative 
predictive value were 100% (95% CI 98.5-100%), 23.1% and 100% 
respectively. Amending the ADP to classify TIMI ≤1 (instead of TIMI 0) as 
low risk increased the proportion of patients falling into the low risk group 
from 19.6 to 41.5%, with sensitivity remaining high at 99.2%. Findings were 
equivalent for the second cohort. hsTn was regarded as elevated if above a 
99th centile cut-off. Serial changes in troponin (deltas) were not used. 
 -13- 
Ng et al (Ng et al., 2001) 
Ng et al describe a ninety-minute accelerated pathway. This relied on the 
use of multi-biomarker point-of-care measurements at 0, 30, 60 & 90 
minutes, and is unlikely to be feasible in most busy EDs. 
Aldous et al (Aldous et al., 2012a) 
Aldous et al assessed the use of hsTnT in 385 patients. 21.3% had AMI. 
hsTnT had a sensitivity of 95.1% (95% CI 88.7-98.1%) by 2 hours, with a 
specificity of 75.6% (95% CI 73.8-76.5%). The sensitivity was not statistically 
different between peak values at 2h and 24h. The addition of a ≥20% delta 
criterion between 0 and 2h samples (with one value ≥99th centile) increased 
specificity to 92.4% (95% CI 90.2-94.3%) but reduced sensitivity to 56.1%. 
Taking ECG results into account reduced the false negative rate to 1.2%. 
The investigators concluded that although the measurement of hsTnT at 0 
and 2h after presentation is not sufficiently sensitive to identify all cases of 
AMI, in combination with the ECG it could potentially safely identify patients 
suitable for early functional testing.
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Study Year of 
Recruitment 
N Entry Criteria ADP Low Risk 
Classification 
Outcome 
ASPECT 11/2007 – 
07/2010 
3582 >18 years 
Symptoms 
suggestive of ACS 
TIMI 0 
No new ECG ischaemia 
Normal point of care biomarker panel at 
0 & 2h (TnI, CKMB, myoglobin) 




ADAPT 11/2007 – 
02/2011 
1975 >18 years 
Symptoms 
suggestive of ACS 
TIMI 0 
No new ECG ischemia 
Normal TnI at 0 and 2 hours 









1635 >18 years 
Symptoms 
suggestive of ACS 
TIMI 0 
No new ECG ischemia 
Normal hsTnI at 0 and 2 hours 
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APACE 11/2007 – 
02/2011 
909 >18 years 
Symptoms 
suggestive of ACS 
TIMI 0 
No new ECG ischemia 
Normal hsTnI at 0 and 2 hours 









1635 >18 years 
Symptoms 
suggestive of ACS 
TIMI ≤1 
No new ECG ischemia 
Normal hsTnI at 0 and 2 hours 




APACE 11/2007 – 
02/2011 
909 >18 years 
Symptoms 
suggestive of ACS 
TIMI ≤1 
No new ECG ischemia 
Normal hsTnI at 0 and 2 hours 
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Christenso
n et al 
06/2000 – 
01/2003 
769 >25 years 
Chest pain 
Age <40, normal initial ECG & no prior 
history of ischaemic chest pain 
Age ≥40 normal initial ECG, no prior 
history of ischaemic chest pain, low risk 
pain characteristics, initial CKMB 
<3.0μg/l, or ≥3.0μg/l with no change in 
ECG or CKMB or Tn from 0 to 2 hours. 
32.5% 
(3.2% in a 
validation 
study – applied 













872 >18 years 
Symptoms 
suggestive of ACS 
No STE on ECG 
Baseline hsTnT <12 ng/l and an 






Hess et al 07/2007- 
02/2010 
2718 >24 years 
Chest pain 




- New ischaemia on initial ECG 
- History of CAD 
- Pain typical for ACS 
- Presentation Tn positive 
 
AND  
Age ≤40 years or 41-50 years with 
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Body et al Testing 
completed 
08/2009 
703 >25 years 
Chest pain within 
24 hours 
 
Presentation hsTnT below detection 
limit for assay (99th centile: 14 ng/l, 
coefficient of variation <10% at 9 ng/L) 
27.7% Sensitivity of 
100% (95% CI 
97.2 to 100%) 
and NPV of 
100% 
 




The Vancouver Chest Pain Rule (Christenson et al., 2006) 
Christenson et al studied a population of 769 patients, and derived a clinical 
prediction rule for the exclusion of 30 day ACS, that was 98.8% sensitive. 
10% of the population had a diagnosis of MI, and a further 11.4% unstable 
angina at adjudication based on assessment of cases at 30 days. They 
conclude that patients are at very low risk of ACS if they have a normal initial 
ECG, no previous ischaemic chest pain, and are younger than 40 years. 
Patients aged 40 years or older were considered low risk if they met the 
same criteria, have low risk pain characteristics (pain not radiating to the 
arm/neck/jaw, pleuritic pain or pain increasing with palpation) and have an 
initial CKMB <3.0 μg/l or an initial CKMB ≥3.0 μg/l but no ECG or serum 
marker increase at 2 hours (CKMB or Tn). 32.5% of patients fell into the low-
risk group. 
Aldous et al validated the sensitivity, but only 3.2% of patients fell into the 
low risk category when it was applied to their recruited population. The 
recruited population in this case was higher risk, 36.2% having an eventual 
diagnosis of ACS. The authors attribute this to their system of pre-hospital 
screening that excludes patients with atypical symptoms (Aldous et al., 
2012b).  
The Vancouver Chest Pain Rule was also validated by Greenslade et al 
using hsTnI as the only biomarker (Greenslade et al., 2013). The rule was 
applied to the ADAPT study population previously mentioned. This included 
1635 patients, 20.4% of whom had ACS. 7.4% of patients fell into the low 
risk group on presentation, with a further 25.6% after 2-hour ECG and 
troponin. Of the 33% of patients assigned to the low risk group (539 
patients), 5.6% had ACS. The sensitivity for ACS at 30 days was 91%, NPV 
94.4%. The authors comment that the sensitivity would have been no higher 
if CKMB rather than troponin had been used. The sensitivity was insufficient 
to enable safe early discharge. An earlier validation of the chest pain rule in 
its original form by Jalili et al found the sensitivity to be 95.1% (95% CI 





Sebbane et al (ultrasensitive copeptin combined with hsTnT) 
(Sebbane et al., 2013) 
Sebbane et al examined the value of combined hsTnT and ultrasensitive 
copeptin drawn at admission for the early rule out of AMI in 194 consecutive 
patients presenting to the ED with chest pain. The combination of 
biomarkers significantly improved the receiver operating characteristic area 
under the curve (AUC) from 0.89 (95% CI 0.85-0.92) for hsTnT alone to 0.93 
(95% CI 0.89-0.97), P = .18. The sensitivity of the dual biomarker strategy 
was 96% for the detection of NSTEMI, with a negative predictive value of 
95%. 
The study by Reichlin et al demonstrated similar findings. This recruited 487 
consecutive patients presenting to the ED with symptoms suggestive of AMI. 
17% of the recruited cohort had a final diagnosis of AMI. The diagnostic 
accuracy of TnT at presentation in the diagnosis of AMI as quantified by 
AUC was 0.86 (95% CI 0.80-0.92), which was significantly higher than the 
diagnostic accuracy of copeptin at presentation (AUC 0.75; 95% CI 0.69-
0.81; p = .009). However, the combination of the 2 markers significantly 
increased the diagnostic accuracy provided by TnT alone, with an AUC of 
0.97 (95% CI 0.95-0.98; p < 0.001). The authors conclude that AMI would 
have been correctly rules out at presentation in 65% of patients, with a 
sensitivity of 98.8%, a negative predictive value of 99.7% and a specificity of 
77.1%. One major limitation is the finding that patients with unstable angina, 
which accounted for 17% of the recruited population after adjudication, had 
similar copeptin levels to patients with other causes of chest pain. Copeptin 
therefore cannot discriminate patients with unstable angina from patients 
with non-ischaemic chest pain (Reichlin et al., 2009). 
Maisel et al also used a copeptin-troponin biomarker combination, coupled 
with the finding of a non-diagnostic ECG. 1967 patients presenting to the ED 
with chest pain were recruited in a multi-site study. Patients were followed 
up for 180 days, with the primary outcome being a diagnosis of AMI. 7.9% of 
patients had a final diagnosis of AMI. A negative copeptin and TnI ruled out 
AMI for 58% of patients, with a negative predictive value of 99.2% (95% CI 




A fourth study took samples from 641 consecutively presenting patients with 
chest pain within the last 12 hours, without ST elevation. Blood was drawn at 
presentation. The sensitivity for the detection of NSTEMI for the combination 
of copeptin and TnI was 90.4%, insufficient to safely rule out NSTEMI at 
presentation (Charpentier et al., 2012). The overall picture for copeptin 
based strategies if therefore mixed. 
High-sensitivity troponin 
Recently, we have seen the development of high-sensitivity troponin, with 
limits of detection around 10-fold lower than conventional assays. Although 
the higher sensitivity allows the detection of myocardial necrosis earlier, 
clinicians have been challenged to decide how best to integrate these 
assays into clinical decision making given their low specificity. In the study 
by Reichlin et al upon adjudication 12 out of 72 patients were felt to have 
been falsely ruled in for AMI based on hsTnT: the corrected diagnoses 
assigned being arrhythmia, myocarditis, pulmonary embolism, hypertensive 
crisis, heart failure, and chest pain of unknown origin (Reichlin et al., 2012). 
Other studies have suggested possible susceptibility of hsTn to biological 
variability across age and sex, and reported elevations in patients with stable 
CAD and heart failure. 
Reichlin et al (Reichlin et al., 2012) 
Reichlin et al studied a one-hour rule-in rule-out of AMI using hsTnT. This 
study included 872 patients from the APACE study cohort. Blood samples 
were drawn at presentation and after one hour. An algorithm for the use of 
hsTnT was developed in a randomly selected 436 patients of the total group, 
and then validated in the other 50% of patients. The adjudicated final 
diagnosis was AMI in 17% of patients, and unstable angina in 12%. 
Classification and regression tree analysis (CART) was used to help develop 
the algorithm. Entered into this were baseline hsTnT, absolute hsTnT 
change within the first hour, age, sex, ECG features, and time since onset of 
symptoms. For rule-out of AMI, the optimal thresholds were selected to allow 
for a 100% sensitivity and NPV. The rule-out criteria were defined as a 
baseline hsTnT <12 ng/l and an absolute change within the first hour of <3 




absolute change within the first hour of ≥5 ng/L. The other variables entered 
into the CART analysis did not improve accuracy. 
After applying the hsTnT algorithm to the validation cohort, 60% of patients 
were classified as rule-out with a sensitivity and NPV of 100%. 17% (72) of 
patients were classified as rule-in, with 12 of these being a false rule-in as 
mentioned above. The remaining 23% of patients were classified into an 
‘observational zone’. 
There were 12 deaths in the whole cohort within 30 days, and 55 within 24 
months. For the rule-out group cumulative survival rates were 99.8% at 30 
days, and 98.1% at 24 months. This study demonstrated a simple algorithm 
for safe rule-out within 1 hour of presentation. There are many questions to 
be explored however: how to deal with the 23% of patients falling into the 
observational zone, and how to assess the resource implications for the 
false rule-in group. The authors raise two notable points: 1- that hsTn should 
be interpreted as a quantitative rather than a qualitative measure of risk due 
to the observation that the proportion of patients with adjudicated AMI rose 
continuously with increasing hsTnT values. In the context of hsTn the terms 
‘troponin positive’ and ‘troponin negative’ should be avoided. Furthermore, 2- 
they highlighted the usefulness of quantitative baseline measures of hsTn 
combined with changes over a given time.  
Body et al also investigated the ability of presentation hsTnT to exclude AMI, 
but used an undetectable hsTnT level as the cut-off (Body et al., 2011a). A 
fifth generation hsTnT was used (99th centile: 14 ng/l, coefficient of variation 
<10% at 9 ng/L). The recruited cohort, which included 703 patients, had an 
adjudicated AMI rate of 18.5%. No patients with a hsTnT value of <3 ng/l at 
the time of presentation had an AMI, giving a sensitivity of 100% (95% CI 
97.2 -100%) and negative predictive valve of 100%. 27.7% of patients fell 
into this ‘rule-out’ group, 2 (1%) of whom died or had AMI within 6 months (1 
peri-procedural AMI, 1 non-cardiac death due to carcinoma). Similar findings 
were seen upon audit after introducing hsTnT into their clinical service. It 
must be highlighted that the hsTnT cut-off was chosen to rule-out AMI. The 
specificity at this level was low (34%, 95% CI 30.2-38.1%). Patients should 




reference population. These patients would need to undergo further 
evaluation. There is still a lot of debate about how best to use hsTn to rule-in 
patients given the low specificity. 
Hess et al (Hess et al., 2012) 
This study sought to develop a clinical prediction rule to identify ED patients 
at very low risk of 30-day cardiac events (AMI, revascularisation, death), 
who might be suitable to discharge for out-patient follow-up. 2,718 patients 
were enrolled following presentation with chest pain without ECG STE or 
haemodynamic instability. 64 variables were recoded, with a decision rule 
generated by statistical analysis. 16.2% of patients suffered a MACE event 
by 30 days. A patient was said to have met the discharge rule if 1- there 
were no new ECG changes, 2- there was no history of CAD, 3- the pain was 
felt to be non-cardiac on clinical assessment, 4- the presentation cardiac 
troponin was negative, and 5- the patient was aged ≤ 40 years, or aged 41-
50 years with a negative troponin at six hours from symptoms. A 
contemporary troponin assay was used. The sensitivity of the chest pain rule 
was found to be 100% for MACE at 30 days.  
I have discussed a large number of biomarker strategies presented in the 
literature. These have been summarised in Table 1.1. All have their 
limitations. Some require biomarker assessment at multiple time points, 
which may not be practicable in a busy ED; others are highly sensitive for 
rule-out but only capture a small number of the presenting population within 
the rule-out; some are complex; and some leave many patients in an 
indeterminate diagnostic zone which palaces the clinician in a management 
quandary. A common theme is the ability to detect AMI as diagnosed by a 
positive troponin, by the measurement of troponin. One should not be 
surprised if the two correlate well. It is important that strategies are also 
assessed on their ability to prognosticate. Unfortunately most of the studies 
do not provide outcome data beyond 30 days. Each healthcare provider will 
need to explore the available options, and apply a strategy that suits their 




2- Aims and Objectives of the Research 
 
I have presented a summary of the evidence base underlying the clinical 
utility of H-FABP measurement. H-FABP levels are predictive of the risk of 
death or MI independent of other clinical risk factors, including troponin, in 
patients presenting with possible ACS. The potential for the use of H-FABP 
levels to aid with the risk stratification of patients presenting to hospital with 
chest pain is of great interest, particularly in the majority group of patients 
who have a negative troponin. 
Research Hypothesis 
We hypothesise that raised H-FABP levels are a marker for significant 
coronary artery disease in patients presenting with chest pain with 
normal troponin concentrations. More specifically: 
- That H-FABP is higher in patients with new onset chest pain that are 
shown to have significant coronary artery disease, and 
- That for patients with new onset chest pain, measurement of H-FABP 
provides information that is additive to the clinical criteria recommended in 
the NICE risk of CAD tables (NICE CG95).  
My MD thesis will be based around the design, implementation, results, and 
analysis of an original prospective observational clinical research study 
conducted to test this hypothesis. In the spirit of the Translational Research 
Grant awarded by Heart Research UK in support of this study, I will explore 
the potential to use the information obtained to generate an early discharge 
rule that could be applied to patients to identify those at very low risk of 
adverse outcomes, that may be suitable for early discharge from the 
Emergency Department. I will attempt to validate this by applying the rule to 







This was a prospective observational study. We recruited 238 patients 
presenting to the ED of the Leeds General Infirmary, a major university-
affiliated teaching hospital in Northern England, between October 2011 and 
November 2012. All patients were considered eligible if their presenting 
symptoms were felt to be suggestive of possible ACS by the assessing ED 
physician in conjunction with the cardiology research physician, or specialist 
research nurse. When in doubt, the final judgment regarding the 
appropriateness of inclusion into the study was made following discussion of 
the case with the principal investigator (STA). Inclusion criteria were 
pragmatic to ensure that the recruited cohort was reflective of the lower risk 
portion of patients presenting to the ED. Appendix A contains details of the 
power calculations undertaken to determine the number of study participants 
required. 
3.1 Inclusion Criteria 
I. Chest pain suggestive of ACS. 
II. Lack of acute ischaemic ECG changes. 
III. Absence of a prior history of coronary artery disease, coronary artery 
bypass surgery, or percutaneous coronary revascularisation. 
For ECG interpretation, criteria set out in the ESC/ACCF/AHA/WHF Expert 
Consensus Document on the Universal Definition of Myocardial Infarction 
were used to define acute ischaemic changes (Thygesen et al., 2007). In the 
absence of LVH and LBBB the criteria were: 
- ST elevation - new ST elevation at the J-point in two contiguous leads 
with the cut-off points: ≥0.2 mV in men or ≥0.15 mV in women in leads 
V2–V3 and/or ≥0.1 mV in other leads. 
- ST depression and T-wave changes - new horizontal or down-sloping ST 
depression ≥0.05 mV in two contiguous leads; and/or T inversion ≥0.1 




A prior history of coronary artery disease was defined as: a known diagnosis 
of angina, prior abnormal cardiac functional assessment, or a prior abnormal 
coronary angiogram. 
3.2 Exclusion Criteria 
I. Obvious non-cardiac cause diagnosed. 
II. Troponin >99th centile at any stage (see below).  
III. Patient unable (e.g. in cases of cognitive impairment), or unwilling to 
consent. 
IV. Serious co-morbidities (e.g. disseminated cancer) or social problems 
preventing participation. 
V. Presentation >24h after onset of index symptoms.  
VI. Pregnancy. 
  
After obtaining patient consent, venous blood samples were drawn at 
admission, 90 minutes later, and also at 12 hours from index symptom 
onset.  
With reference to exclusion criterion II. Troponin levels were not known at 
the time of patient screening. Recruited patients who developed a troponin 
>99th centile at any stage, were excluded from subsequent parts of the 
study, apart from monitoring for the occurrence of major adverse 
cardiovascular events. All patients had a ≥12 hour troponin taken as part of 
routine clinical care. 
Demographic and relevant clinical baseline data (including known prognostic 
factors) were collected at the time of consent or during the hospital stay. 
This was facilitated by integration of the research documentation into the 
normal printed ED patient management protocol and record sheets 
(Appendix B). Patients were admitted to the ED Clinical Decisions Unit to be 
managed in line with standard local protocols, including any necessary initial 
investigations / specialty reviews, serial ECGs, and to await ≥12 hour 




Following discharge, all troponin negative patients (<99th centile) underwent 
CT scanning to obtain a coronary artery calcium score. In addition, these 
patients were seen (in the majority of cases within two weeks) in a 
specialised rapid access chest pain clinic under the supervision of a 
Consultant Cardiologist. Patients were investigated with reference to 
standard local and national clinical assessment and investigation protocols 
(NICE CG95), as deemed appropriate by the assessing physician. The out-
patient clinical assessment formed part of the patient’s standard care, aimed 
at ascertaining the cause of their original symptoms and excluding 
obstructive coronary artery disease where this was suspected clinically. 
From the study perspective, this follow-up was designed to look for both 
obstructive and non-obstructive coronary artery disease by combining a CT 
coronary calcium score, a marker of atheroma burden, with appropriate 
assessment to exclude obstructive coronary artery disease where this was 
clinically indicated. 
All patients were followed up for the occurrence of major adverse 
cardiovascular events for a minimum of 6 months after index assessment – 
defined as death from cardiovascular cause, MI, or coronary 
revascularisation procedure. Monitoring of long-term survival status is 
planned through the UK Office of National Statistics. The hospital electronic 
records system was used to identify the occurrence of MI or coronary 
revascularisation procedure. This method was found to be robust and 
reproducible when used for the FAB2 study, during which it was validated on 
a random sample of patient hospital records and follow-up questionnaires 
(Viswanathan et al., 2010). As our hospital is the sole provider of emergency 
care within the city of Leeds, and the only tertiary referral site for primary 
angioplasty within West Yorkshire, it is expected that using this method we 
were able to identify the majority of cardiovascular events. In cases of 
patients who were not local to our area, records were sought from their local 
care provider if they had continued investigation elsewhere, and where 





3.3 Patient Consent 
Allowing for the busy ED environment and the fact that many patients are in 
discomfort on presentation, a two-stage consent process was deployed. This 
has been used successfully with ethical approval in previous studies 
undertaken in our department. 
Verbal consent was taken for the initial set of presentation blood samples. 
Patients usually have blood tests taken at this stage anyway for their routine 
clinical care, and so this stage did not involve additional phlebotomy. 
This was followed by full written consent prior to the 90 minute samples 
allowing sufficient time for patients to read the patient information sheet, and 
consider the matter further. In cases where the patient did not want to 
proceed further with the study, the initial research samples taken were 
destroyed. Appendix B contains copies of the Patient Information Sheet and 
Consent Form used. 
At the time of their CT scan or clinic review, patients were asked to consider 
providing consent for long term storage and use of their samples in further 
studies (denoted the FAB3-CTx (extension) Study). A copy of the Patient 
Information Sheet and Consent Form used can be found in Appendix C. 
3.4 Ensuring Safe Research Conduct 
A comprehensive education strategy was put in place to ensure that all 
members of the ED staff involved with the clinical care of recruited patients 
were familiar with pertinent aspects of the study. This took the form of 
informative e-mails and posters, combined with presentations at the 
mandatory ED staff induction sessions for each cohort of new ED doctors, 
and a presentation at the ED clinical governance meeting. 
3.5 Measurement of Cardiac Biomarkers 
All venous blood samples were analysed for troponin I, H-FABP, B-type 
natriuretic peptide (BNP), and high-sensitivity C-reactive protein (hsCRP). 
The routine clinical measurement of troponin I (TnI Ultra - Siemens 




“troponin negative”, i.e. those below the clinical decision limit. Troponin was 
the only biomarker measured live, and the results at each time point were 
made available to the clinical team to aid with patient management. The 
availability of troponin results at presentation and 90 minutes later was not 
standard practice within our ED at the time of initiating this study. The 
measurement of admission troponin for study patients brought practice in 
line with NICE guidelines (CG95). The release of 90 minute troponin results 
was felt necessary from an ethical perspective and is part of practice in 
some UK centres. As recruited patients who developed a troponin >99th 
centile at any stage were excluded from subsequent parts of the study, apart 
from monitoring, this is not expected to impact on study findings. 
The availability of admission and 90 minute troponin results formed one of 
the focuses of the education strategy, in particular to ensure that patients 
could not be discharged based on a negative early troponin result. The 
release of early troponin results to the clinical team was intended to augment 
patient care, allowing ACS therapies to be commenced at the earliest 
opportunity following the diagnosis of ACS, in line with current NICE 
guidance. Furthermore, it was felt that this would be an aid to service 
development within the ED. As part of service development work stemming 
from this study, the routine measurement of admission troponin has 
subsequently been introduced across the Leeds Teaching Hospitals NHS 
Trust. 
All FAB3-CT study blood samples were centrifuged and stored at -70°C for 
batch assays to be carried out for measurement of H-FABP, BNP, and 
hsCRP at a later stage. Sample stability tests previously conducted in our 
department showed no significant change in H-FABP concentrations after 
storage for 12 months using this method. H-FABP was measured using the 
RANDOX Immunoturbidometric Immunoassay, on a Siemens 1800 Advia 
Instrument platform. Assays used for the other biomarkers were: 
 hsCRP - Siemens Immunoturbidometric Immunassay, on a Siemens 
1800 Advia instrument platform. 
 TnI Ultra - Siemens Chemiluminescence Immunoassay, on 




 NTproBNP - Siemens Chemiluminescence Immunoassay on the 
Siemens Immulite 2000 platform. 
3.6 ECG Interpretation 
For the purpose of patient management, ECGs were interpreted by the 
clinical team. For the purposes of the study all ECGs were assessed 
according to the pre-agreed criteria already stated. A report for each was 
recorded in the study database. 
3.7 Genetic Samples 
A blood sample for DNA, and saliva sample for RNA were taken at the ‘90 
minute’ time point for processing and storage. It is our intent that these 
samples will be used for future collaborative research following further grant 
submissions. Similarly, BNP and hsCRP will not be a focus for this thesis. 
3.8 CT Coronary Calcium Score 
A 64 slice Siemens scanner was used to take a total of 40 sections with a 
tomographic slice thickness of 3 mm covering the area between the carina 
and the diaphragm, proceeding in a caudal direction. Images were obtained 
at 100-ms/slice scanning time using ECG-triggered acquisition and sampled 
from 60 to 80% of the R-R interval. A calcified lesion is conventionally 
defined as >3 contiguous pixels with a peak attenuation of at least 130 
Hounsfield units – being scored using the method of Agatston et al (Agatston 
et al., 1990). Scans were reported by our collaborating Consultant 
Radiologist (MD). 
3.9 Rapid Access Chest Pain Clinic Assessment  
In most cases clinical review was performed within 2 weeks of referral and 
involved “one-stop” assessment. Documentation of essential study data 
points was aided by the use of a purpose designed clinic document pack, 
which included a summary guide to current NICE guidelines (CG95) – see 
Appendix C. Additional investigations were arranged at the discretion of the 




was dictated by these results combined with the judgement of the clinician, 
and expressed wishes of the patient. Consequently, we were able to obtain 
clinical information additional to that obtained at the time of index 
assessment in the ED.  
Results of the CT coronary calcium score were made available to the 
assessing doctor to aid clinical management. The use of CTCS is part of 
NICE guidelines for the assessment of patients with estimated pre-test 
likelihood of CAD from 10-29% (CG95). The availability of the result for 
patients within other pre-test likelihood categories may have influenced 
secondary prevention measures and investigation decisions, but was felt to 
be an ethical requirement in this case. As most patients with CAD have 
coronary calcification, the availability of these results is likely to have 
increased the detection of significant CAD, which was an objective of the 
RACPC from the study perspective. Consideration of secondary prevention 
measures is routine for all patients seen in a RACPC, and unlikely to have 
affected event rates within the relatively short follow-up period of this study. 
3.10 Study Endpoints 
These are the predetermined study endpoints, as defined in the study 
protocol. 
 
3.10.1 Primary Endpoint: Presence of significant coronary artery disease 
defined as the finding of an Agatston CT coronary calcium score >10. 
 
The cut-off of an Agatston calcium score >10 was a pragmatic decision. This 
was based on its use as a cut-off level in some of the larger coronary artery 
calcification studies. An example of this is the study by Blaha et al, which 
assessed annualised all-cause mortality rates in 44,052 consecutive 
asymptomatic patients referred for coronary artery calcium (CAC) testing. 
The mean follow-up of the cohort was 5.6 +- 2.6 years. A total of 19,898 
patients (45%) had no CAC on screening, whereas 5,388 (12%) had low 




mortality rates for CAC = 0, CAC 1-10, and CAC >10 were 0.87, 1.92, and 
7.48 deaths / 1000 person-years, respectively (Blaha et al., 2009). 
 
3.10.2 Secondary Endpoint: Clinical demonstration of obstructive 
coronary artery disease based on clinical assessment of patients supported 
by a functional test of myocardial ischaemia and a stenosis of >50% in at 
least one artery at the time of coronary angiography. 
 
3.10.3 Tertiary Endpoint:  Occurrence of a major cardiovascular event in 
the first 6 months after index assessment – defined as death from a 
cardiovascular cause, myocardial infarction, or coronary revascularization 
procedure. 
 
The study was powered to assess the primary endpoint. It was appreciated 
that the recruited cohort size may be inadequate to assess secondary and 
tertiary endpoints. 
3.11 Data Security 
A System Level Security Policy is in place to ensure the security and safety 
of confidential patient information. 
3.12 Ethics 
An Integrated Research Application was made and all necessary approvals 
obtained for this study, including approval form the East Yorkshire & North 
Lincolnshire Research Ethics Committee (REC Reference 10/H1304/36).  
3.13 Funding 
Funding for this study was secured via a grant from Heart Research UK 
(Grant Reference RG2586). This grant included provision for specialist 
research nurse support. An additional grant was obtained from the Leeds 
Teaching Hospitals Charitable Foundation Research and Development Fund 




adoption was achieved on the UK Clinical Research Network Portfolio 






239 patients were recruited between 4th October 2011 and 23rd December 
2012. The chart below summarises patient flow through the various stages 
of the study. 
 
Figure 4.1 Diagram depicting patient flow through the study. 
RACPC – Rapid Access Chest Pain Clinic, ETT – exercise tolerance 
test, +ve – positive, -ve – negative, eq – equivocal. 
 
8000 patients with chest pain present to the ED of the Leeds Teaching 
Hospitals each year – demographic data is not available for patients who 




4.1 The ‘Average Patient’ Journey 
A record was made of the date and time of each study stage conducted in 
the ED. Using mean times, the diagram below demonstrates the typical 
journey through the ED for the ‘average patient’. 
 
 





















Acceptable time windows were considered to be 60 minutes from ED 
registration to phlebotomy for admission bloods, and 90-120 minutes later 
for 90 minute bloods. This allowed for the need for triage, clinical 
assessment, an ECG, and verbal consent prior to withdrawal of ED 
admission bloods. Written consent had to be taken prior to 90 minute bloods, 
and occasionally patients were in transit through the department or attending 
for a chest radiograph at the second phlebotomy time.  
4.2 Recruitment Characteristics 
As recruitment was being undertaken in a busy tertiary centre ED, it was 
agreed that most patients would be recruited within a 0900 – 1700 Monday 
to Friday time frame. This is reflective of the increased availability of 
research staff within day-time hours, and was designed to minimise impact 
on the ED. 
89% of patients were recruited on week days, as opposed to 11% on 
Saturday / Sunday (Figure 4.3). This is not expected to affect the 














4.3 Patient Presentation Characteristics 
The recruited patients had index chest pain onset times spread throughout 
the day, but a majority experienced their pain in the early morning (between 
0500 and 1100, see Figure 4.4). Reflective of this, the ED arrival time of 
patients also had a morning tendency, as shown in Figure 4.5. In this case 
the study recruitment patterns are likely to have contributed to this, although 
the findings are in keeping with other studies describing an early morning 
peak in chest pain onset times and ED chest pain presentations (Ekelund et 
al., 2012).  
 
 
Figure 4.4 Index chest pain onset time. 
The assessing ED physician documented an index chest pain onset time for 
each patient. In the majority of cases this was the worst / most prolonged 
episode, occasionally the last episode if this was deemed significant. 77% of 
patients presented within 6 hours of their index chest pain, with a median 
presentation time of 3:09 hours, and range of 0:02 to 23:10 hours (Figure 




arrival to the ED. Patients who presented more than 24 hours after their 
index pain were excluded from participation: this was chosen as an 
exclusion criterion due to the potential for H-FABP levels to normalise after 


















4.4 Patient Demographics 
4.4.1 Age 
A broad age range was represented in the recruited patient population, 
varying from 30 to 87 years, with a median age of 53 years 11 months 
(Figure 4.7).  
 
 
Figure 4.7 Histogram of age at recruitment (in years). 
 
Split by sex, females patients were on average older than males by about 




Figure 4.8 Histogram of age at 
recruitment by sex (in years).
 Number Mean Age  
Male 132 53 P = .002 







55% of recruited patients were male and 45% female. This is in keeping with 
expected presentation patterns for chest pain patients. 
 
Figure 4.9 Patients by sex. 
 
4.4.3 Ethnicity 
86% of patients categorised their ethnicity as ‘British’. There was a wide 
range of ethnic groups represented as shown in Figure 4.10. The ethnicity 
categories were collected from standardised hospital records, and were not 













4.5 Vascular Risk Factor Profile 
25% of patients were current smokers, with a further 16% being ex-smokers 
(Figure 4.11). 
 
Figure 4.11 Smoking status. 
Other risk factors are shown in Table 4.1. 
 
- Family history of premature ischaemic heart disease (IHD) was defined 
as a first or second degree relative with IHD present at an age younger 
than 50 years. In cases where the patient could not provide a family 
history, for example due to being adopted, this was recorded as 
‘unknown’. 
- Hypertension was recorded if the patient was on treatment for this, or if 
they reported the diagnosis. 
- Hypercholesterolaemia was defined as a recorded total cholesterol >6.47 




active treatment for this. In cases where a baseline cholesterol level had 
never been measured, this was marked as ‘unknown’. 
- Diabetes was recorded if the patient reported the diagnosis. 6% of 
patients had diabetes (14 patients), of which 2 had type I diabetes. 
- Due to the lack of availability of routine weight and height measurements 
in the ED, obesity was recorded in the main based on the subjective 
assessment of the attending physician.  
- In order to maintain high quality data collection, the study design allowed 
for two opportunities for this data to be collected. A record was made 
initially by the attending ED physician using standardised ED 
documentation pathways into which the research was integrated. This 
was cross checked and further assessed during rapid access chest pain 
clinic assessment. Incomplete data was limited to 3%. 
 
Table 4.1 Risk Factor 
Profile. 
FHx – family history, 
IHD – ischaemic heart 
disease. 
 % 
Risk factor Present  Absent Unknown 
FHx of premature IHD 26 67 7 
Hypertension 36 62 3 
Hypercholesterolaemia 30 60 11 
Diabetes 6 91 3 




4.6 Presentation Haemodynamics 
The study inclusion criteria targeted low-medium risk chest pain patients. In 
our institution these patients are managed on a protocol driven pathway 
within the ED Clinical Decisions Unit (CDU). This involves observation with 
sequential ECGs pending the results of a 12 hour from index pain troponin 
result. All patients had been deemed haemodynamically stable by the 
assessing ED physician. The histograms below represent the first recorded 
observations taken in the ED. Although there are a few patients with 
readings outside the normal range at triage, perhaps due to on-going pain at 
the time, all patients were haemodynamically stable prior to admission to the 
CDU. 
 




4.7 Troponin Levels 
Overall 11.3% (N = 27) of recruited patients had a contemporary troponin 
level >99th centile reference level. In 15 of these patients the troponin level 
was raised on the ED admission sample, with a further 9 patients becoming 
troponin positive on the 90 minute sample. For clarity, where the term 
troponin negative or positive is used, this refers to whether the level is below 












4.8 CT Coronary Calcium Scores 
CT Coronary Calcium scans were performed on 199 patients, of which 96 
had a zero Agatston score. Scores ranged from 0 to 4114. The graphs below 
demonstrate calcium score by age and admission H-FABP level (Figure 4.14 
and Figure 4.15). Statistical correlations will be explored later in this chapter. 
 
Figure 4.14 CT Calcium Score (log Agatston score) by age (years). 
















Figure 4.15 CT Calcium Score (log Agatston score) by admission H-FABP 




It is well documented that coronary artery disease is more common in 
patients with renal failure. No particular trend is seen within the data 
from this study - Figure 4.16 shows calcium scores plotted against 
estimated glomerular filtration rate (eGFR). eGFR is given in 
mls/min/1.73m2 throughout this document. 
 
Figure 4.16 Log CT Calcium Score against eGFR. 
4.9 H-FABP Levels 
For troponin negative patients admission H-FABP levels ranged from 1.3 to 
17.1 μg/l, with a mean of 3.8 μg/l (N=198). For troponin positive patients the 
range was 2.6 to 106.4 μg/l, with a mean of 13.9 μg/l (N=23). Figure 4.17 














Figure 4.17 Histogram of admission H-FABP levels for all patients (μg/l). 






Figure 4.18 H-FABP levels at 90 minutes (A) and 12 hours (B) - for troponin 







H-FABP levels showed an increasing trend with age, as shown in Figure 
4.19. In addition there was an increasing trend with lower eGFR (Figure 











Figure 4.20 Admission H-FABP (μg/l) by eGFR . 
4.10 H-FABP Dynamic 
H-FABP levels were taken at three time points. As levels rise and fall quickly 
with cardiac ischaemia, the change from one reading to another may contain 
useful information. 
Figure 4.21 demonstrates the percentage change in H-FABP between the 
three sample points, for troponin negative patients. It is interesting to note 
that more patients had falling levels between admission and 90 minutes, 
than rising. The same is true comparing 90 minute to 12 hour levels, 
although to a lesser degree. 
 






Figure 4.21 Percentage H-FABP change for troponin negative patients. A - 






The mean CT calcium score (CTCS) was higher for patients with a less than 
20% change in H-FABP level between readings as compared to those with a 
greater than 20% change (213 vs. 126) – Figure 4.22. These means were 
not however statistically significantly different from each other, p = .81 



















4.11 Relating H-FABP to CT Calcium Score 
In the introductory chapter I outlined the evidence behind H-FABP as a 
prognostic marker in patients presenting with possible ACS. The relationship 
between H-FABP levels and CTCS, as a marker of coronary artery atheroma 
burden, is therefore of major interest, and the prime aim of this mechanistic 
study. 
As demonstrated in Table 4.2 below, there is a statistically significant 
positive correlation between H-FABP at all time points and CTCS, for 
admission H-FABP τ = .22, p (one-tailed) <.01. From the table you will note 
that age and renal function also correlate with both H-FABP and CTCS. 
Nonetheless, the positive correlation between H-FABP and CTCS still 
holds true after accounting for age and eGFR using second-order partial 















Table 4.3 Correlating H-FABP with CTCS, controlling for age and eGFR. 
 
4.12 Patient Outcomes 
Patients participating in the study were seen in a Rapid Access Chest Pain 
clinic under the supervision of a Consultant Cardiologist. Appendix C 
contains a copy of the specifically designed clinic documentation used for 
this, which includes investigation guidance in keeping with current NICE 
recommendations (CG95). As this was an observational study, clinicians 
were at liberty to investigate and treat patients in accordance with their own 
judgment. 
CG95 contains within it criteria against which patient symptoms can be 
matched to assign a symptom category. 9% of patients fell into the ‘Typical 
Angina’ group, 15% into the ‘Atypical Angina’ group, and 76% into the ‘Non-
Anginal’ chest pain group (Table 4.4). Symptom categories were assigned to 
a total of 190 patients. Figure 4.23 shows the distribution of patients 
according to their NICE CG95 assigned risk category for coronary artery 
disease, which takes into account the typicality of symptoms, age, sex, and 
other risk factors such as smoking status, total cholesterol level and diabetic 
state. This was recorded in 185 cases. Some patients could not be assigned 












Typical angina 17 8.9 
Atypical angina 28 14.7 
Non-anginal chest pain 145 76.3 
Total 190 100.0 
 
Table 4.4 RACPC Assigned Symptom Category (Prior to Investigation). 
 
Figure 4.23 RACPC Assigned NICE Risk Category for CAD. 
 
3% of patients were commenced on treatment without further investigation. 
This occurred where the clinician made a clinical diagnosis of angina, 




to investigate further – this may have reflected a combination of the patient’s 
wishes, age and comorbidities. 21% of patients were not felt to require 
further investigation and were directly discharged from clinic. The rest 
underwent outpatient investigation: 31% undergoing stress 
echocardiography; 17% a nuclear myocardial perfusion scan; 6% an 
invasive coronary angiogram; 2% a CT coronary angiogram; with the 
majority of the remainder undergoing a treadmill exercise ECG. Figure 4.1 
provides a summary of the investigations undertaken and their results. 
Of the patients who were sent for further outpatient investigation, 13 (12%) 
had a positive functional or anatomical test. Of the 195 patients seen in 
clinic, 5 patients met the predefined study protocol secondary outcome 
(clinical impression of angina, supported by a positive functional test for 
cardiac ischaemia and a coronary stenosis of >50%). The final NICE CG95 
diagnostic category given for patients after completion of investigations is 
shown in Table 4.5. 
 





Typical / Atypical angina 23 12 
Non-anginal chest pain 170 88 
Total 193 100 
Table 4.5 RACPC Assigned Symptom Category (After Investigation). 
 
Patients were followed up for a median of 406 days (range 207-616). 6 pre-
defined tertiary outcomes occurred: 2 deaths from a cardiovascular cause, 1 
myocardial infarct, and 3 coronary revascularisation procedures. Death 
certificates and / or clinical notes were obtained to substantiate cause of 
death. Patients will remain under surveillance for death via UK Office of 




Prevalent acute myocardial infarcts were accounted for – i.e. acute 
myocardial infarction diagnosed on the initial ED visit.  
The third universal definition of myocardial infractions was used. Myocardial 
infarction was diagnosed by a rise and/or fall of cardiac biomarker values (in 
this case cardiac troponin I) with at least one value above the 99th percentile 
upper reference limit and with at least one of the following: 
 Symptoms of ischaemia. 
 New or presumed new significant ST-segment-T wave changes or 
new left bundle branch block. 
 Development of pathological ECG Q waves. 
 Imaging evidence of new loss of viable myocardium or new regional 
wall motion abnormality. 
 Identification of an intracoronary thrombus by angiography or 
autopsy. 
4.13 Pre-specified Analyses 
In this section I have presented analyses pre-specified in the study protocol. 
 
4.13.1 Primary Analysis  
Comparison of the area under the H-FABP concentration curve (for 
admission, 90 minute and 12 hour samples) for patients with Agatston CT 








Figure 4.24 ROC Curve, H-FABP vs Agatston CT calcium score split 
(positive state ≥10, negative state <10). 
 
Comparison of the mean H-FABP level for patients with Agatston CT 
coronary calcium score ≥10 as compared to a score <10. For patients with a 
CTCS <10 the mean admission H-FABP level was 3.50 μg/l (N = 109), as 




were similar findings for the 90 minute and 12 hour H-FABP levels (see 
Table 4.6). 
 







Mean 90 minute 
H-FABP 
μg/l  
Mean 12 hour 
H-FABP 
μg/l 
CTCS <10 3.50 (N 109) 3.20 (N 89) 3.02 (N 91) 
CTCS ≥10 4.34 (N 80) 4.92 (N 72) 3.92 (N 66) 
 P = .001 P = .003 P = .001 
Table 4.6 Mean H-FABP Level by CT Calcium Score. 
 
4.13.2 Secondary Analysis  
Comparison of the area under the H-FABP concentration curve (admission, 
90 minutes and 12 hour samples) for patients with clinical demonstration of 
obstructive coronary artery disease (based on clinical assessment of 
patients supported by a functional test of myocardial ischaemia and a 
stenosis of >50% in at least one artery at the time of coronary angiography).  
 
Only 5 patients met the predefined study protocol secondary outcome. There 
were too few events within this category to produce a ROC curve. The study 
was not powered to fully examine secondary or tertiary endpoints.  
 
4.13.3 Tertiary Analyses   
4.13.3.1 Quantitative relationship between actual value of H-FABP and 
calcium score. 





4.13.3.2 H-FABP as part of a multifactor model to predict primary and 
secondary endpoints.  
The ability of admission H-FABP to predict a combined triple outcome, in 
conjunction with other risk factors, was assessed using backward conditional 
logistic regression. The combined triple outcome included: Agatston CT 
calcium score >10; a positive functional assessment for cardiac ischaemia in 
the presence of a coronary stenosis greater than 50%; and the occurrence 
of myocardial infarction, coronary revascularisation, or death from a 
cardiovascular cause. Prevalent acute myocardial infarcts were accounted 
for – i.e. patients who had a negative troponin level on admission, which 
then became positive at a subsequent time point, were also included within 
the triple outcome. A rule-out strategy on admisison is most useful clinically. 
I have therefore focussed on building a rule-out model using admission H-
FABP. 
Table 4.7 shows the outcome of this regression analysis. Included in the 
analysis were age, eGFR, and admission H-FABP as continuous variables. 
Included as dichotomous variables were gender, family history, smoking 
status, and the presence / absence of hypertension, hypercholesterolaemia 
and diabetes. Patients with evidence of ischaemia on their ECG were 
excluded from the study, but some patients included did have more minor 
abnormalities such as ECG criteria for left ventricular hypertrophy, or a first 
degree AV block. The ECG was therefore also included as a variable: 
completely normal versus minor abnormality. 
The least powerful predictors were excluded in a stepwise fashion, as seen 
in Table 4.7. The four predictors remaining by the final stage were age, 
admission H-FABP, gender, and hypercholesterolaemia. By including these 
four predictors it was possible to build a regression model able to correctly 
assign 75.3% of cases (see Table 4.7). 
Some notable observations are: 
 Admission H-FABP is a more powerful predictor than some 





 H-FABP is also a more powerful predictor than minor ECG 








Table 4.7 Backward Conditional Binary Logistic Regression for Prediction of 
Combined Triple Outcome. 
A – Step 0 Classification, B – Variables in the Equation Steps 1–7, C – 












4.14 H-FABP as a Diagnostic Marker 
There is limited information in the literature about the reference values for 
the RANDOX Laboratories immunoturbidimetric assay used in this study. 
Our own local published reference data was obtained using redundant 
serum samples from patients in primary care and those attending secondary 
care out-patients (excluding renal and cardiology clinics) (Carless et al., 
2013). Although this is an accepted method for obtaining samples, we 
cannot be sure that some of these patients did not have underlying coronary 





been thoroughly investigated to exclude both obstructive and non-
obstructive CAD, and within the recruited population therefore we can select 
a group who can be considered ‘normal’. Looking at H-FABP levels in this 
population could therefore provide useful information. 
From the recruited population I have selected patients with a negative 
troponin, normal ECG, CT Agatston score of 0, and no secondary or tertiary 
study outcomes (including any label of angina or atypical angina). Table 4.8 












Table 4.8 Admission H-FABP Percentiles for 'Normal' Patients. 
N = 73. Normal = normal ECG, CT Agatston score < 0, and no 
secondary or tertiary study endpoints (including any diagnostic label of 
angina or atypical angina). 
4.15 Exploring the Diagnostic Potential of H-FABP 
It is worth highlighting at this stage that this study was not powered for 
secondary and tertiary outcomes. The exploration of ideas at this stage is 
useful however. In this section I would like to explore the diagnostic potential 
of admission H-FABP as a dichotomous variable, combined with admission 
ECG and troponin. We will call this a ‘triple rule-out strategy’, whereby 
patients are labelled as not having a problem if their admission ECG is 
normal, combined with a normal troponin level, and admission H-FABP level 




it is important for it to work at this time point. This has potential to save 
hospital and patient time currently spent waiting for 12 hour blood samples, 
by allowing us to select low risk patients potentially suitable for early 
discharge. 
Naturally, whenever we choose a specific cut-off for a diagnostic blood test, 
there is always a trade off between sensitivity and specificity. Initially I would 
like to explore the potential of the triple rule-out strategy at differing H-FABP 
percentiles to exclude the combined endpoint of CTCS > 10, secondary and 
tertiary endpoints. 
Table 4.9 shows the triple rule-out strategy for different admission H-FABP 
percentile cut-offs. The negative predictive value is better for lower H-FABP 
cut-offs, at the expense of fewer patients falling into the rule-out. At the 50th 
centile H-FABP cut-off sensitivity is 76% and specificity 37%. 
 






Predictive Value  
% (N/N) 
Positive 








57.7 (75/130) 49 (25/51) 31 74 
4.1 (70th 
Centile) 
56.5 (52/92) 44.9 (40/89) 50 51 
3.16 (50th 
Centile) 
66.1 (37/56) 48.8  (61/125) 76 37 
Table 4.9 Triple Rule-out Strategy for different H-FABP cut-offs. For 





As most patients will have some degree of coronary calcification with age, 
perhaps it is more important for this triple rule-out strategy to be able to 
exclude secondary and tertiary endpoints alone. This is more relevant from a 
clinical perspective. The CT calcium score contains important prognostic 
information, but according to NICE CG95 cannot be used in the diagnostic 
pathway except in low risk patients (the 10-29% CAD risk group, 
representing only 22.7% of the recruited patient population). Table 4.10 
shows diagnostic information for different H-FABP cut-offs for the detection 
of secondary and tertiary outcomes, not including calcium score. 
 



















96.2 (125/130) 13.7 (7/51) 58 73.9 
4.1 (70th 
Centile) 















Table 4.10 Triple Rule-out Strategy for different H-FABP cut-offs. For 
exclusion of secondary / tertiary outcomes (not CT calcium score). 
 
Employing the triple rule-out strategy to detect secondary and tertiary 
outcomes, using a H-FABP cut-off at the 50th centile, has a 96.4% negative 
predictive value (95% CI 86.6%-99.4%), and sensitivity of 83% (95% CI 
50.9%-97.1%). 56 out of 181 patients would have fallen into the triple rule-




and 2 falsely ruled out. One of the false rule-outs was a patient who 
presented very early, only 33 minutes after index chest pain. This will be 





5.1 Key Study Findings 
Chest pain presentations account for a significant healthcare burden. There 
are now well established pathways for dealing with the treatment and 
investigation of patients who have indeed had a myocardial infarct. The 
reality, however, is that the majority of patients presenting to our ED (79% 
according to the FAB2 study) do not fall into this category (Viswanathan et 
al., 2010). Within this larger group most patients are found not to have a 
cardiac problem, but some do, and a small group go undetected carrying 
forward significant risk of coming to harm from death and myocardial 
infarction. This high risk troponin negative group are very hard to detect 
clinically. Any prognostic aid that allows us to identify low and high risk 
patients would be a major step forward. H-FABP has been shown to have 
the potential to do this. It is important to state however, that the extent to 
which the risk is reversible in the high risk group is unknown. In this study 
88% of recruited patients were not felt to have had a cardiac aetiology to 
their presenting symptoms, after review / investigation in the RACPC. If H-
FABP could help us avoid having to follow-up some of these patients, this 
would have major implications in reducing patient anxiety, time spent 
attending clinic and investigations, and would conserve resources. 
In the FAB3-CT study we targeted our attention onto the lower risk end of 
the spectrum of patients presenting to the ED. We did this by excluding 
patients with a prior history of coronary artery disease, haemodynamic 
instability, an ischaemic ECG, or troponin level >99th centile. Nonetheless, 
we have seen that there is still a high prevalence of traditional 
cardiovascular risk factors within this group: with 25% being current 
smokers; 16% ex-smokers; 36% having hypertension and 30% 
hypercholesterolaemia. Similarly, when matched to current NICE CG95 risk 
categories for coronary artery disease, only 26% of these patients were in 
the <10% risk category. A further 15% fell into the 61-90%, and 3% into the 




One of the primary aims of this study was to provide information about how 
H-FABP may be predicting risk. We used coronary calcification as a marker 
of coronary artery atheroma burden. There was a statistically significant 
positive correlation between H-FABP and CT calcium score, 
independent of age and renal function. 
We assessed the diagnostic ability of H-FABP as a continuous variable to 
diagnose CTCS >10, and the clinical demonstration of obstructive coronary 
disease. Used on its own H-FABP was poor at doing this, with areas under 
the ROC curve around 0.6. When used as part of a multifactorial model to 
predict these endpoints H-FABP was, however, a more powerful 
predictor than some traditional risk factors such as smoking status, 
diabetes, and hypertension, as well as renal function. 
H-FABP showed the greatest promise when used as a bivariate within what 
we termed a ‘triple rule-out’ strategy. Here, H-FABP was used alongside the 
ECG and troponin to help identify patients at low risk of obstructive coronary 
artery disease and tertiary events, over the median follow-up period of 406 
days (range 207-616) (death from a cardiovascular cause, myocardial 
infraction, coronary revascularisation). Using a H-FABP cut-off at the 50th 
centile (3.16 μg/l for the Randox Immunoturbidometric Immunoassay), the 
triple rule-out strategy had a 96.4% negative predictive value (95% CI 
86.6%-99.3%), and sensitivity of 83% (95% CI 50.8%-97.1%). The positive 
predictive value was low at 8%, so this model could not be used to rule-in 
patients likely to have a problem, just to rule out patients who were at low 
risk. 31% of the recruited population fell into the rule-out group (56 out of 
181 patients). Of the 56 patients ruled out, 54 were a correct rule-out. Only 
2/56 were a false rule-out. It is useful to have a look at these two patients to 
see if improvements to the rule-out model can be made. 
- Patient 1: A 43 year old man who had presented to the ED only 33 
minutes after his index chest pain. Both ECG and troponin were 
normal (including 12hr troponin). H-FABP was not raised beyond the 
50th centile at any time point. He was allowed home after a period of 
observation and sequential ECGs. CTCS was 0. He was seen in the 




60% NICE CG95 risk score for CAD. No further investigations were 
deemed necessary. 317 days after his index ED attendance he 
presented with an MI and received coronary intervention. Although 
not picked up by the triple rule-out strategy, he was also not picked up 
by current practice. 
- Patient 2: A 70 year old man who presented 5:23 hours after index 
chest pain. ECG and troponin were normal, including H-FABP < 50th 
centile at all time-points. After clinical review he was felt to require in-
patient investigation with a coronary angiogram and received 
coronary intervention based on the finding of a coronary stenosis. It is 
possible that his presenting symptoms were nonetheless non-cardiac. 
If the triple rule-out was to be used clinically, all patients would obviously still 
require clinical review by a senior physician prior to discharge, to help 
establish a diagnosis and exclude serious non-cardiac caused such as 
pulmonary embolus and aortic dissection. In addition, given the known 
release characteristics of H-FABP, patients presenting earlier than one hour 
should have sampling delayed until at least one hour from index symptoms. 
There are some important limitations to these secondary analyses, which will 
be considered below.  
5.2 Study Conduct 
Overall, the study was well received by patients, who felt that they had 
benefitted from taking part. As a reflection of this, over 99% provided 
consent at a second stage to allow long term follow-up and use of their 
samples for further research. Few patients refused initial consent, and there 
was a low rate for investigation and clinic non-attendance.  
Investigation in the RACPC seems to have been thorough. I had hoped that 
this would have followed current NICE CG95 guidance more rigidly to allow 
relevant information to be collected about how this was working in practice: 
this would have produced additional interesting material for publication. 
CG95 does not advocate the use of treadmill ETT, which was used in some 




study. The investigating Cardiologist was at liberty to investigate as they saw 
fit, and this was in-line with standard local practice. NICE CG95 has not yet 
been fully adopted in most areas of the UK due to it’s reliance on cardiac 
CT, for which there are on-going capacity issues. 
Blood samples were overall taken within good time, allowing for patient 
movements through a busy ED, with many potential delaying factors. 
5.3 Study Limitations 
All patients were considered eligible if their presenting symptoms were felt to 
be suggestive of possible ACS by the assessing ED physician in conjunction 
with the cardiology research physician, or specialist research nurse. When in 
doubt, the final judgment regarding appropriateness of inclusion into the 
study was made following discussion of the case with the principal 
investigator (STA). It is accepted that there are potential differences of 
having chest pain assessed by different healthcare professional groups. This 
is however reflective of real life practice for the management of this group of 
patients with heterogeneous presentations. All recruited patients were 
managed according to a standardised pathway, which should have 
minimised variability in practice. 
The availability of troponin results at presentation and 90 minutes later was 
not standard practice within our ED at the time of starting this study. This will 
have impacted on patient management. It will have facilitated the earlier 
initiation of ACS therapy, and the availability of more than one troponin 
reading allowed the utilisation of the international definition for the diagnosis 
of MI. The measurement of admission troponin for study patients brought 
practice in line with NICE guidelines (CG95). The release of 90 minute 
troponin results was felt necessary from an ethical perspective and is part of 
practice in some UK centres. As recruited patients who developed a troponin 
>99th centile at any stage were excluded from subsequent parts of the study, 
apart from monitoring, this is not expected to impact on the study findings. 
The results of a CT calcium score may have influenced management in the 
RACPC. The use of CTCS is part of NICE guidelines for the assessment of 




availability of the result for patients within other pre-test likelihood categories 
may have influenced secondary prevention measures and investigation 
decisions, but was felt to be an ethical requirement in this case. A high score 
may have resulted in a lower threshold for further cardiac investigation, or 
the initiation of secondary prevention medications. From the study 
perspective the RACPC assessment was intended to allow the detection of 
clinically significant CAD, so this is not expected to have impacted 
adversely. The initiation of risk modifying medications is unlikely to have 
affected event rates within the relatively short follow-up period of this study. 
The predominant day-time recruitment of patients may have impacted on the 
type of patient recruited, or even the ACS rate. Within the limits of the study 
it is not possible to quantify this. 
There are some important limitations to the secondary analyses that should 
be considered. This study was not powered for secondary and tertiary 
events, so the analysis of these will be underpowered. This is reflected in the 
wide confidence intervals. It is also not ideal to draw main conclusions based 
on secondary analyses. Furthermore, deriving a H-FABP cut-off then 
applying it to the same population may have unanticipated consequences. 
There are also limitations of drawing conclusions about a triple rule-out 
strategy involving ECG ischaemia and troponin elevations when the study 
excluded patients with both of these parameters. The proposed strategy 
therefore requires validation on an independent patient cohort. 
5.4 Applying FAB3-CT Findings to Previously Recruited 
Patient Populations 
In order to gain confidence with the potential for H-FABP to be used as a 
diagnostic tool within a rule-out strategy, I would like to take advantage of 
the availability of a previously recruited patient population to test how it 
would have worked if applied to them. The FAB2 study, from which some 
analyses were published in 2010 using 12 hour blood samples (Viswanathan 
et al., 2010), included almost 500 patients who also had admission H-FABP 
and troponin levels taken. The study recruited patients with possible or 




years or above with chest pain of possible or definite cardiac aetiology were 
deemed eligible for recruitment, irrespective of ECG changes. Of those 
patients recruited, 79% had a negative troponin results ≥12 hours from pain. 
We have obtained updated survival status through the UK Office of National 
Statistics (censorship date 18 June 2013), and now have over six years of 
follow-up data for these patients. In this section I would like to present some 
de-novo analyses from this patient population, applying the triple rule-out 
strategy discussed above in order to help establish the long term prognostic 
abilities of this rule-out model. 
Incorporating a 50th percentile H-FABP cut-off into the triple rule-out strategy 
was associated with the highest negative predictive value and sensitivity 
combination for secondary and tertiary outcomes in the current FAB3-CT 
study (Table 4.10). FAB3-CT used the Randox Laboratories 
Immunoturbidimetric Immunoassay, whereas the FAB2 study used the 
Randox Laboratories Biochip Array Assay. Our own Chemical Pathology 
Department has previously set reference values for both assays using 
reference populations (Carless et al., 2013). The H-FABP 50th centile for the 
Biochip Array assay was 1.63 μg/l. 
Figure 5.1 shows a Kaplan Meier curve for death event-free survival, split by 
the 50th centile H-FABP triple rule-out strategy (admission H-FABP <50th 
centile, normal ECG, and admission troponin <99th centile). You will note 
from the inset table that 19% of patients fell into the rule-out category, with a 
marked difference in the number of deaths seen between the two groups. 
There were only 2 deaths in the rule-out group over the six year follow-up 
period (2.2% all-cause six year mortality), as compared to 79 in the group 
that did not meet triple rule-out criteria (20.6% all-cause six year mortality). 
This equates to an all-cause six year mortality sensitivity of 97.5% (95% CI 
90.5%-99.6%); specificity of 22.4% (95% CI 18.4%-26.9%); negative 
predictive value of 97.8% (95% CI 91.4%-99.6%) and positive predicative 
value of 20.6% (95% CI 16.7%-25.0%). Clearly H-FABP correlates with 
survival but H-FAB also correlates with age. The mean age for patients in 
the rule-out group is 49.93 years, as apposed to 62.23 years in the non rule-
out group (p = .001). UK Office for National Statistics data released in 




and 0.79% for people aged 60-64 years. The differing mortality seen 
between the rule-out and non rule-out groups is not therefore a factor of age 
alone. 
Figure 5.2 demonstrates the same Kaplan Meier curve with H-FABP 
removed from the model, resulting in poorer event separation between the 
two groups. This helps to clearly demonstrate the significant contribution of 
H-FABP to the accuracy of the rule-out model. The mean age of patients in 
this rule-out group is 57.09 years, versus 64.31 in the non rule-out group (p 
= .001). For comparison, Figure 5.3 is a Kaplan Meier curve for death event 
free survival, split by ECG and 12-hour troponin <99th centile alone, 
equivalent to our current practice – patients with a normal ECG and 12-hour 
troponin had a six year all-cause mortality of 10.7%. 
 
Figure 5.1 Kaplan Meier curve for death event free survival, split by 50th 
centile H-FABP triple rule-out strategy. 
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Figure 5.2 Kaplan Meier curve for death event free survival, split by double 
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Figure 5.3 Kaplan Meier curve for death event free survival, split by double 
rule-out strategy alone (ECG and 12-hour Troponin <99th centile 
alone). 
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5.5 Conclusion & Future Direction 
The analyses demonstrate the great potential for H-FABP to be used as part 
of a triple rule-out strategy, guided by clinical assessment, alongside the 
ECG and troponin to identify low risk patients as they present to the ED. H-
FABP provides additional prognostic information on top of current standard 
practice at an earlier time point, and could allow earlier discharge of patients 
from hospital in a safe manner, potentially avoiding unnecessary out-patient 
investigation. 
Validation of the triple rule-out strategy on the FAB2 study population has 
been presented for mortality only. Work is currently on-going to update the 
follow-up of the large FAB2 cohort for other tertiary events. This will allow 
the triple rule-out strategy to be validated further. The strategy would also 
benefit from external validation. 
Modelling the triple rule-out strategy on the FAB2 study population, 
demonstrates that patients meeting the rule-out only had a 2.2% six year 
mortality, as compared to a six year mortality of 10.7% if discharged on the 
basis of current practice ECG / 12-hour troponin alone. This echoes findings 
of the FAB1 study which demonstrated zero mortality in the troponin / H-
FABP negative group at six months (Kilcullen et al., 2007). It is worth noting 
that FAB3-CT and FAB2 used different H-FABP assays, which may limit the 
external validity of the finding. There is nonetheless growing evidence for the 
utility of H-FABP measurement to identify patients at very low risk as they 
present to the ED.  
There are certainly a number of exciting research avenues that could be 
explored. This study used CTCS in the investigation strategy in part to 
reduce radiation exposure to this low risk population, but CT technology has 
moved on at such a quick pace that it is now possible to do a full contrast CT 
coronary angiogram for similar radiation doses. CT angiography could be 
used for future research projects. Another avenue that could be explored is 
H-FABP measurement before and after stress echocardiography, where 
stress echo has already been requested on clinical grounds. The biomarker 




randomised study utilising H-FABP clinically in one arm would also be 
useful, although such a study was not deemed necessary for the introduction 




6- Introducing H-FABP into Clinical Practice 
A working group was convened to discuss potential modifications in the 
Leeds Teaching Hospitals chest pain pathways. Amongst other options, the 
possibility of introducing H-FABP as part of a triple rule-out strategy was 
explored. On the basis of these discussions, a Business Case was 
formulated exploring potential modifications in current practice. This is 
included below, and has formed the basis for on-going discussions. 
As part of this service development process, in October 2014 admission 
troponin measurement was made available for all patients presenting to the 








Introduction of Chest Pain Accelerated Discharge 
Protocol 
Abdel-Rahman ST, Webster A, Barth JH, Hassan T, Hall AS 
 
Executive Summary 
Around 14,000 patients with chest pain attend the LTHT Emergency Department (ED) 
each year. The purpose of this business case is to identify modifications in the LTHT 
chest pain pathway that could utilise advances in biomarker technology to facilitate 
early safe patient discharge, as part of an accelerated discharge protocol (ADP). 
Objectives / Benefit 
· To bring LTHT practice in-line with current NICE guidance. 
· To allow the safe discharge of selected low-risk patients within the 4-hour ED 
window. 
· To reduce Clinical Decision Unit (CDU) admissions for chest pain. 
· To reduce CDU Rapid Access Chest Pain Clinic (RACPC) referrals. 
Options Considered 
1- Introduction of ED admission troponin (alone). 
2- Introduction of ED admission troponin, combined with H-FAB measurement. 
3- An alternative biomarker strategy. 
4- No change. 
 
Preferred Option & Cost 
· Introduction of ED admission troponin, combined with H-FAB measurement 
· Cost – £16,800 plus £11,250 for the respective components. 
 
Benefit Appraisal 
· ED admission troponins would be available for patient benefit, bringing LTHT 
practice in-line with current NICE guidance. 
· 20% of chest pain patients could be discharged within the ED 4-hour window. 
Equating to an anticipated accumulated 550 bed day saving. 
· Most patients discharged on the ADP would not require RACPC referral. 
 
Risk Analysis 
We would be the first centre worldwide to introduce this method of risk assessment. 
The proposal is based on extensive research performed within LTHT. The new 
pathway will be subject to audit at one month, and again at six months. 
 
Timetable for Implementation 








ADP Business Case 2 
 
Setting the Scene. Around 14,000 patients with chest pain attend the LTHT 
Emergency Department (ED) each year. Although the majority (>80%) do not have a 
final diagnosis of acute coronary syndrome (ACS), they often undergo lengthy 
assessment to exclude it. This is because our current practice is based on risk 
stratification utilising a troponin taken 12 hours after pain onset. The mean length of 
stay for a patient admitted to the Clinical Decisions Unit (CDU) on the Chest Pain 
Protocol is just under 12 hours.  
There is a growing interest in ‘early’ cardiac biomarkers that could allow the risk 
stratification of patients sooner. The purpose of this business case is to identify 
modifications in the LTHT chest pain pathway that could utilise advances in 
biomarker technology to facilitate early safe patient discharge, as part of an 
accelerated discharge protocol (ADP).  
Why are changes needed? 
· Patients presenting with chest pain account for a significant proportion of our 
ED and acute medical inpatient workload. 
· Our current chest pain pathway does not fully comply with NICE guidance. 
· Changes would allow us to identify and treat ACS at an early stage – this is 
prognostically important for our patients. 
· An accelerated discharge protocol will speed up the diagnostic journey for 
patients, save 550 bed days per annum and relieve increasing pressure on 
the ED, CDU, and Cardiology admission ward. 
 
Current LTHT Practice. At present, patients presenting to the ED are triaged 
according to ECG findings, haemodynamic state, and prior cardiac history. The 






ADP Business Case 3 
 
Figure 1. Current LTHT Practice. Numbers represent patients between August 
2012 and September 2013. RACPC = Rapid Access Chest Pain Clinic.  
 
NICE Compliance 
Current NICE Guidance ('CG 95, Chest Pain of Recent Onset') states: 
· 1.2.4.1 Take a resting 12-lead ECG and a blood sample for troponin I or T 
measurement ON ARRIVAL in hospital. 
· 1.2.5.2 Take a second blood sample for troponin I or T measurement 10– 12 
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Early troponin measurement (i.e. on ED admission) is not currently available within 
LTHT. 
Data from the FAB3-CT Study completed at LTHT in May 2013 using a translational 
research grant from Heart Research UK, supports the clinical utility of early troponins 
(Abdel-Rahman et al. Awaiting publication). 
· 239 CDU patients were recruited. Blood samples were drawn on admission, 
90 minutes later and at 12 hours from chest pain onset.  
· Of the 26 patients who were troponin positive, 68% were positive on their ED 
admission sample. Identifying ACS sooner ensures that appropriate therapies 
are given at the earliest opportunity. 
 
Current Service Performance. At present, treatment and investigation decisions 
are made on the basis of clinical assessment combined with the use of an ECG and 
12 hour troponin. Examining the performance of current practice is essential as a 
comparator to assess the potential benefits / pitfalls of any proposed service 
changes. 
The FAB2 study, performed at LTHT, collected information on 1080 consecutive 
patients with chest pain ?ACS as they presented to the ED (Viswanathan K, 2010). 
79% of these patients had negative troponin results ≥ 12 hours from pain. We have 
obtained updated survival status for these patients through the UK Office of National 
Statistics (censorship date 18 June 2013), and now have over six years of follow-up 
data. 
The Kaplan-Meier plot shown in Figure 2, illustrates survival from recruitment out to 
just over six years. As this was an observational study, these patients were managed 
in line with current LTHT practice. The patients have been split into two groups 
based on ECG and troponin findings. The green line represents patients with a 
normal ECG and 12 hour troponin: patients who meet the current discharge criteria 
subject to clinical assessment  (which is in line with national standards). The 
mortality in this group for the six-year period was 10.7%. Patients discharged using 






ADP Business Case 5 
 
Figure 2. Kaplan-Meier Curve for Patients Managed According to Current LTHT 
Practice. Patients are split by ECG and 12 hour troponin findings. 
 
 
Relevant constraints in current service provision: At present, the Chemical 
Pathology laboratory does not process troponin assays overnight.  
 
Management arrangements for delivery of plan: The Department of Emergency 
Medicine will oversee delivery of service changes arising from this business case. 
· Dr Andrew Webster, ED Clinical Lead for CDU, will be the clinical lead for 
implementation in the ED. 







ADP Business Case 6 




Preferred option to be decided by February 2014 
Implementation to be completed by September 2014 
 
Fit with Trust / National Strategy 
· To ensure LTHT chest pain pathways are in line with current national 
guidelines, in keeping with the trust’s medium term strategic objective of 
‘continuing to improve standards of care and patient safety’. 
· To update the pathways in line with the current evidence base, in keeping with:  
o The Trust’s vision ‘to be a locally, nationally, and internationally 
renowned centre of excellence for patient care’.  
o The Trust’s goal ‘to achieve the best possible clinical outcome for every 
patient, every time’, and to ‘expand the boundaries of healthcare’. 
 
Options Considered 
1 – Introduction of ED admission troponin (alone) 
As specified within NICE CG95 ‘Chest Pain of Recent Onset’, but not yet 
implemented at LTHT. 
Our own local data suggests that this would allow up to 68% of patients who have a 
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Figure 3. Option 1 - Introduction of ED admission troponin (alone). 
 
Pros 
· Brings LTHT practice in line with current NICE guidance. 
· Allows earlier treatment of ACS. 
Cons 
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Risk Analysis 
· Patients with a negative admission troponin will still have to wait for a negative 
12-hour troponin prior to being considered for discharge. Measures will need 
to be put in place to ensure that a patient cannot be discharged on the basis 
of a negative admission troponin alone. 
· A trial of making early troponins accessible has already been undertaken 
successfully within ED, as part of the FAB3-CT study, which recruited patients 
from the LGI ED between October 2011 and November 2012. ED admission 
and 90 minute troponins were released for recruited patients live onto the 
results server. Staff training was introduced at the ED induction sessions, 
combined with clear labels as to the timing of the troponin sample on the 
results server. No adverse events were seen. 
Cost 
· Additional 8000 troponin assays (8000 x £2.10 = £16,800). 
· Chemical Pathology advise that there is no additional service costs for the 
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2- Introduction of ED admission troponin, combined with H-FAB measurement 
 
Figure 4. Option 2 - Introduction of ED admission troponin, combined with H-
FAB measurement. 
 
Heart-type fatty acid binding protein (H-FABP) is a cytoplasmic protein found 
abundantly within cardiac myocytes.  Its small size allows it to be readily released 
into the circulation after both myocardial ischaemia and infarction. 
There is a growing evidence base supporting the high potential of H-FABP levels in 
the early diagnosis of ACS, the risk assessment of patients presenting with chest 
pain, and emerging evidence suggesting that H-FABP levels are closely related to 
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summary of the current evidence base for the diagnostic and prognostic potential of 
H-FABP. 
Three studies have now been performed within LTHT examining the clinical potential 
of H-FABP. Overall these studies have included in excess of 2700 patients. Details 
of the first two (published in the Journal of the American College of Cardiology) are 
given in appendix A. The FAB3-study was completed in May 2013, and is awaiting 
publication pending the results of two patent applications. 
We have identified a risk stratification strategy that could be applied to patients on 
admission to the ED, which is able to identify an exceptionally low risk group suitable 
for early discharge. This utilises a ‘Triple-Rule-Out’ strategy, whereby patients fall 
into the low risk group if they have 1- a normal presenting ECG, 2- an admission 
troponin I < 99th centile, and 3- an admission H-FAB <50th centile. This EDP was 
devised using FAB3-CT study data, and has been validated by applying it to the 
FAB2 study population for which we now have over six years of follow-up data. 
Modelling performed on the FAB2 study population estimated that 20% of presenting 
patients would fall into the low risk group, with only a 2.2% observed six-year 
mortality (Figure 5) – the first death occurred almost two years into follow-up. None 
of the patients identified as low risk on admission went on to have a 12-hour troponin 
above the clinical decision cut off. You will recall for comparison that patients 
discharged according to current practice have a 10.7% six-year mortality. 
All patients would obviously still require clinical review by a senior doctor prior to 
discharge from the ED, to help establish a diagnosis and exclude serious non-
cardiac causes such as pulmonary embolus and aortic dissection. Given the known 
release characteristics of H-FAB, patients presenting earlier than 1 hour from index 
chest pain, should wait one hour before initial blood tests are taken. Patients not 
meeting the Triple-Rule-Out will be managed in accordance with current practice, 
and await a 12-hour troponin on CDU. 
Patients falling into the Triple-Rule-Out have such a low mortality risk, that they could 
be discharged directly from the ED within the four-hour ED wait window. Data from 
the FAB3-CT study demonstrates that the Triple-Rule-Out strategy has a 96.4% 
negative predictive value for the detection of clinically significant coronary artery 
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defined as 1- the clinical demonstration of obstructive coronary artery disease based 
on clinical assessment of patients supported by a functional test of myocardial 
ischemia and a stenosis of >50% in at least one artery at the time of coronary 
angiography, or 2- the occurrence of a major adverse cardiovascular event in the 
first six months after index assessment (defined as death from a cardiovascular 
cause, myocardial infarction, or coronary revascularisation).  For patients without a 
prior history of coronary artery disease, It would not be considered routine, therefore, 
for these patients to be assessed in the RACPC upon discharge, although this could 
be arranged when the assessing ED Physician feels it is appropriate. If symptoms 




Figure 5. Kaplan-Meier curve showing mortality for FAB2 study patients split 
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The green line represents the low risk group identified by the Triple-Rule-Out 
strategy on ED admission, proposed for early discharge. 
Pros 
· ED admission troponins would be available for clinical benefit as with option 1. 
· 20% of patients could be discharged early without having to wait for a 12-hour 
troponin result. Equating to an anticipated accumulated 550 bed day saving 
(1629 patients anticipated to be discharged on ADP, with reduced length of 
stay from 12 to 4 hours). 
· Reduced admission pressure on CDU & Cardiology Admission Ward. 
· Reduced referrals to the RACPC. 
· Quicker pathway for patients. 
Cons 
· Cost of introducing admission H-FAB and troponin. 
· There are no anticipated negative consequences for the Department of 
Cardiology. The EDP is relevant in the main for patients who are currently 
managed on CDU. Patients not falling into the EDP will be managed in-line 
with current practice. 
 
Risk Analysis 
· We would be the first centre worldwide to introduce this method of risk 
assessment. The proposal is based on extensive research performed within 
LTHT. 
· The pathway will be audited at one month and again at six months. This will 
record patient flow through the pathway, combined with mortality and ACS 
rates on patients discharged on the ADP. 
 
Cost 
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· Plus 2500 H-FAB assays (2500 x £4.50 = £11,250). 
· Total cost £28,050. 
 
 
Figure 6. Proposed pathway according to option 2 - the 'Triple-Rule-Out' 
strategy. Numbers represent expected patient flow. 
3- An alternative biomarker strategy 
A literature search has been performed to identify any other accelerated discharge 
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an exhaustive summary of the literature base, the most relevant papers are 
discussed below. 
Greenslade et al has examined the use of high sensitivity troponin in combination 
with the Vancouver chest pain rule. Of the 1635 patients recruited, 33% were 
assigned as low risk within 2 hours, although 5.6% of these went on to have ACS. 
They conclude that the sensitivity is insufficient to enable safe early discharge 
(Greenslade JH, 2013). 
In 2012 the ADAPT Trial investigators reported a 2-hour accelerated diagnostic 
protocol tested on a cohort of 1,975 patients (Than M, 2012). This used a 
combination of ECG, TIMI risk score, zero and 2 hour contemporary troponin 
measurement. 20% of patients were identified as low risk. Only 1 (0.25%) patient 
had a MACE event within the one month follow-up period, but there was a relatively 
high therapeutic (18.3%) and procedural (2%) intervention rate amongst the ADP 
negative group. Using this strategy could therefore allow early discharge, but all the 
patients would need to be seen in the RACPC. No long term follow-up data is 
provided for the early discharge group. 
Another published study incorporating 1,285 consecutive presenting patients (Ng SM, 
2001) used point of care testing for a combination of CK-MB, myoglobin, and 
troponin I. Combined with ECG findings and clinical assessment 40% of presenting 
patients could be allowed home using 90 minute from ED biomarker analysis. There 
was however, a 1% re-admission rate within the first month with unstable angina 
(0.8%) or myocardial infraction (0.2%), and no long-term mortality follow-up is 
available for the discharged patients. 
Lastly, following discussions at the 2013 Cardiology Consultant ‘Time-Out’ meeting, 
Prof Hall was asked to review a recent BMJ Commentary (Shah AS, 2013) (Siu) (Ng 
SM, 2001), which explored the use of high-sensitivity troponin at zero and 3-hours. It 
was noted that$the proposed pathway did not cover all types of patient outcomes 
(e.g. Troponin >99th centiles at time zero and 3 hours without >20% change; 
Troponin<99th centile at time zero and >99th centile at 3 hours but <50% change). 
The proposed pathway was also based on theory rather than clinical data showing 
that it worked. 
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4- Do nothing 
This was not considered a viable option, given the fact that our current chest pain 
pathway does not fully comply with NICE guidance. 
 
Preferred Option 
2- Introduction of ED admission troponin, combined with H-FAB measurement 
 
Benefits Appraisal 
· ED admission troponins would be available for patient benefit, bringing LTHT 
practice in-line with current NICE guidance. 
· Allow up to 20% of ?-cardiac chest pain patients to be discharged within the 
ED 4-hour wait time. 
· Reduced CDU admissions and length of stay for patients on the chest pain 
protocol. 
· Reduced CDU referrals to the RACPC. 
The pathway will be audited at one month and again at six months. This will record 
patient numbers, combined with mortality and ACS rates on patients discharged on 
the ADP.  Data will be obtained from the Department of Informatics on CDU length of 
stay. CDU RACPC referral numbers will also be monitored, combined with admission 
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Appendix A 
Summary of Current H-FABP Evidence Base 
 
Heart-type fatty acid binding protein (H-FABP) is a cytoplasmic protein found 
abundantly within cardiac myocytes (Glatz et al. 1997).  Its small size (15 Kd) allows 
it to be readily released into the circulation after both myocardial ischaemia and 
infarction. Following myocardial infarction serum levels peak after around 6-8 hours, 
and return to normal within about 24 hours (Glatz, van der Voort and Hermens 2002; 
Glatz et al. 1994). Although highly cardiac-specific, small concentrations are found in 
tissues outside the heart. Other limitations include its renal excretion (like troponin) 
potentially making it less useful in patients with renal impairment, and the relatively 
narrow diagnostic time window. Elevated H-FABP levels are reported in patients with 
atrial fibrillation, atrial flutter, and after electrical cardioversion, and care should be 
used therefore if being used as a biomarker in these patient groups (Mazovets et al. 









Figure 7 Three dimensional structure of human H-FABP. 
Biochemical Journal (2001) 354, 259-266. 
 
There is a growing evidence base supporting the high potential of H-FABP levels in 
the early diagnosis of ACS, the risk assessment of patients presenting with chest 
pain, and emerging evidence suggesting that H-FABP levels are closely related to 
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A.1 H-FABP as a Diagnostic Marker 
There are now a good number of studies published in this area, although many 
include fewer than one hundred patients, and used differing H-FABP assays. 
Nonetheless the overall evidence base supports the utility of H-FABP for the early 
diagnosis of ACS. 
In a study of 705 patients presenting with suspected cardiac chest pain, in blood 
drawn at presentation, H-FABP was demonstrated to be superior to CK-MB, 
myoglobin and troponin for the detection of MI (area under ROC curve 0.86 (95 % CI 
0.82-0.90) (Body et al. 2011). Although in this study no single marker could enable 
clinically acceptable exclusion of MI on its own, the combination of troponin I and H-
FABP was found to be the optimal biomarker combination. Similarly, in 485 patients 
Gururajan et al demonstrated H-FABP, measured 3-6 hours after the onset of pain, 
to be a good discriminator between patients with ACS as compared with those felt to 
have non-cardiac symptoms and normal controls (area under ROC 0.97, 95% CI 
0.95-0.98)(Gururajan et al. 2010). 
The absolute reported sensitivity and specificity of H-FABP for the early diagnosis of 
ACS varies in the literature, probably reflective of the differing assays used, 
combined with variations in the way ACS is categorised and the time blood samples 
were drawn. In general the sensitivity averages around 80%, and the specificity 
around 75%. Perhaps more important is that the evidence base shows H-FABP to be 
superior in many instances to troponin for the diagnosis of ACS early following 
symptom onset. In the study by Charpentier et al using samples from 677 patients 
with suspected ACS on admission to the ED, H-FABP was predictive of the 
diagnosis of ACS with an OR of 4.65 (95 % CI = 2.39 – 9.04), specificity of 96.8%, 
but low sensitivity of 13.5% (Charpentier et al. 2010). In this study H-FABP was not 
felt to add significant additional information on top of standard diagnostic tools. Figiel 
et al demonstrated a similar specificity for diagnosing non-ST segment elevation MI 
in 100 patients, using blood drawn at presentation, although sensitivity in this study 
was found to be much higher at 94.7% (Figiel et al. 2008). Cavus et al reported a 
sensitivity of 97.6% on samples taken during the first hour from presentation (Cavus 
et al. 2006). H-FABP has a high negative predictive value for MI, 93% at 0 to 3 
hours from pain onset, increasing to 97% at 3 to 6 hours. Combining H-FABP 
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Numerous other studies support the use of H-FABP for the early diagnosis of MI 
(Nakata et al. 2003; Okamoto et al. 2000; Orak et al. 2010; Ruzgar et al. 2006; Valle 
et al. 2008; Kim et al. 2011; Kim et al. 2010). 
A.2 H-FABP as a Prognostic Marker 
One of the largest published studies on H-FABP, conducted by our Department, 
examined the ability of H-FABP levels to predict long-term mortality in patients with 
confirmed ACS. This used samples taken at 12-24 hours after chest pain from 1448 
patients. H-FABP was strongly predictive of all-cause mortality at one year after 
index hospital admission, independent of traditional clinical risk factors, and across 
the whole spectrum of ACS. Of great interest, was the ability of H-FABP levels to 
separate troponin negative patients into a low and high-risk group. Unstable angina 
patients with a low H-FABP level (<5.8 µg/l) had a 1-year all-cause mortality of 2.1%, 
whereas patients with levels above this cut off had a mortality of 22.9%. The 
occurrence of a negative test for both H-FABP and troponin was associated 
with zero mortality prior to six months (Kilcullen et al. 2007).  
Figure 8 All-cause mortality by Troponin and H-FABP clinical cut-offs. 
Note the ability of H-FABP levels to separate patients with negative troponin 
into low and high risk groups. TnI = Troponin I, - = below clinical cut-off, + = 
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A follow on study further examined the role of H-FABP in the low to medium risk 
population by using 1080 consecutive presenting patient with suspected rather than 
confirmed ACS (Viswanathan et al. 2010). 79% of these patients had negative 
troponin results ≥ 12 hours from pain. The risk of death or MI increased with 
increasing H-FABP levels, confirming the ability to H-FABP to predict events 
independent of other clinical risk factors, including troponin assessed by an ultra 
sensitive assay. The findings from these two studies are in keeping with those 
reported by O’Donoghue et al using samples taken form patients recruited into the 
OPUS-TIMI 16 trial (O'Donoghue et al. 2006). 
Garcia-Valdecasas et al demonstrated that H-FABP,  measured within the first 3-6 
hours after the onset of chest pain, was not only more sensitive than troponin I in the 
early diagnosis of MI, but was an independent predictor of events within a 6-month 
follow-up (Garcia-Valdecasas et al. 2011). 
Numerous other studies confirm the prognostic potential of H-FABP (Suzuki et al. 
2005; Erlikh et al. 2005) 
A.3 Relating raised H-FABP to Stenotic Atherosclerosis 
To my knowledge there is only one study examining the correlation between H-FABP 
levels and coronary stenoses. In a study of 93 patients with ACS presenting within 
two hours of onset of chest pain, H-FABP was measured at 2, 4, and 6 hours from 
symptom onset. All patients underwent coronary angiography. Peak H-FABP levels 
were seen at 4 hours. Measured at 2 hours the sensitivity of H-FABP for at least 50 % 
stenosis was 70%, rising to 85% at four hours for  ≥50% stenosis, and 88% at four 
hours for ≥70% stenosis. The sensitivity and positive predictive value for 
revascularisation was 89 and 80% respectively at four hours (Kalay et al. 2010). 
There are no published studies examining the correlation between H-FABP and total 
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Extract taken from study protocol. 
A.1 Sources of Variability 
(i) RANDOX H-FABP assay – Coefficient of Variation at clinical decision 
point <5%  
(ii) 64 Slice Cardiac CT – Sensitivity and Specificity for presence of 
significant CAD >99%.  
(iii) Within observer variation in identifying coronary calcium score ≤1%.  
(iv) Between observer variation in identifying coronary calcium score ≤1%. 
A.2 Prevalence of Primary Endpoint 
A recently published study of 44,052 subjects with no known CAD that were 
assessed by CT calcium scoring and followed for an average of 5.6 yrs 
(Blaha et al., 2009). A total of 19,989 (45%) subjects had a calcium score of 
0 while an additional 5,388 (12%) had a score of between 0 and 10. After 
correction for other known risk factors, the risk of death was 2x higher in the 
second group than the first. A further 18,766 (43%) had a score of >10 and 
an adjusted relative risk of death that was 5x higher than for those with a 
score of 0.  
A.3 Prevalence of Secondary Endpoint 
Studies that have performed coronary angiography in unselected patients 
with suspected acute coronary syndrome that were found to be ‘troponin 
negative’ report the presence of significant coronary artery disease to be 




A.4 Measured Differences in H-FABP in FAB-2 Study 
(Viswanathan et al., 2010) 
(i) H-FABP concentration at 12 hours after onset of symptoms for patients 
found to have a normal troponin I concentration and alive vs. dead at 12 
months: 2.56 µg/L (SD 1.91; n=733) vs. 4.93 µg/L (SD 3.05; n=26). 
Difference in H-FABP 2.37 µg/L or 92.6% (p<0.0001).  
(ii) H-FABP concentration at 12 hours after onset of symptoms for patients 
found to have a normal troponin I concentration and “alive with no MI” vs. “ 
dead or with MI” prior to 12 months: 2.54 µg/L (SD 1.86; n=719) vs. 4.56 
µg/L (SD 3.27; n=40). Difference in H-FABP 2.02 µg/L or 79.5% (p<0.0001). 
A.5 Power Calculation 
The proportion of ‘troponin negative’ patients with significant CAC is 
assumed conservatively to be 43% (Blaha et al., 2009) and those with 
stenotic coronary artery disease as 23% (deFilippi et al., 2000). We estimate 
that recruitment of at least 86 patients that are subsequently shown to have 
a CAC score >10 and at least 86 patients with a CAC score ≤10 is required 
to reliably detect a difference in H-FABP of 0.5 µg/L (>90% power at the 5% 
significance level). However, we are opting to recruit a total of 250 patients 
(estimate 107 CAC>10 & 143 with CAC ≤10) and will ensure that a total of 
>200 (estimate 86 CAC>10 & 114 with CAC ≤10) complete the study as far 
as the Rapid Access Chest Pain Assessment Clinical assessment. This will 
also ensure that any patients excluded due to study withdrawal or inter-
current events are substituted and that the target numbers are attained. This 
will allow reliable detection of a difference in H-FABP as small as 0.3 
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